{
    "id": "dbpedia_2651_0",
    "rank": 42,
    "data": {
        "url": "https://patents.google.com/patent/WO2018229202A1/en",
        "read_more_link": "",
        "language": "en",
        "title": "WO2018229202A1 - Mesoionic imidazolium compounds and derivatives for combating animal pests - Google Patents",
        "top_image": "https://patentimages.storage.googleapis.com/c7/d6/c4/f7dc943a7d0e43/imgf000002_0001.png",
        "meta_img": "",
        "images": [
            "https://patentimages.storage.googleapis.com/c7/d6/c4/f7dc943a7d0e43/imgf000002_0001.png",
            "https://patentimages.storage.googleapis.com/b5/f1/94/77b135cadd55a9/imgf000003_0001.png",
            "https://patentimages.storage.googleapis.com/6c/7d/60/e75a76e2e3bfc0/imgf000003_0002.png",
            "https://patentimages.storage.googleapis.com/fd/bb/86/3e39f416476570/imgf000010_0001.png",
            "https://patentimages.storage.googleapis.com/3b/ca/3b/468c72c08e7d4a/imgf000017_0001.png",
            "https://patentimages.storage.googleapis.com/8b/3b/c9/7757849c9fd823/imgf000017_0002.png",
            "https://patentimages.storage.googleapis.com/cf/01/de/398bdaed25095e/imgf000018_0001.png",
            "https://patentimages.storage.googleapis.com/0b/ad/20/a7d881327e9424/imgf000018_0002.png",
            "https://patentimages.storage.googleapis.com/85/3a/97/f7ba0dcfa4ca28/imgf000019_0001.png",
            "https://patentimages.storage.googleapis.com/2a/1d/36/08fc4041385c80/imgf000020_0001.png",
            "https://patentimages.storage.googleapis.com/00/b7/4d/5e11bb61506f38/imgf000020_0002.png",
            "https://patentimages.storage.googleapis.com/10/99/ae/71b2cb3c15665a/imgf000020_0003.png",
            "https://patentimages.storage.googleapis.com/da/a9/bd/d3b3f55edd6d35/imgf000021_0001.png",
            "https://patentimages.storage.googleapis.com/4f/2c/78/6bc65af7e99d2c/imgf000021_0002.png",
            "https://patentimages.storage.googleapis.com/f2/54/4f/97d2674c0ceef9/imgf000021_0003.png",
            "https://patentimages.storage.googleapis.com/e3/91/b2/67ab74ca96b20a/imgf000023_0001.png",
            "https://patentimages.storage.googleapis.com/21/8c/c1/f10071a0bf36a0/imgf000024_0001.png",
            "https://patentimages.storage.googleapis.com/fb/37/04/3eda8452132637/imgf000024_0002.png",
            "https://patentimages.storage.googleapis.com/46/e1/7b/c9cbde3ea4c24d/imgf000025_0001.png",
            "https://patentimages.storage.googleapis.com/19/0c/c1/c663ca7dfef988/imgf000026_0001.png",
            "https://patentimages.storage.googleapis.com/75/eb/03/bdd0cb651396ef/imgf000027_0001.png",
            "https://patentimages.storage.googleapis.com/cf/25/7f/b7478dd80de9ad/imgf000028_0001.png",
            "https://patentimages.storage.googleapis.com/7e/3c/71/abb63bee4ed41e/imgf000029_0001.png",
            "https://patentimages.storage.googleapis.com/fc/62/fd/d2b380a64b791f/imgf000030_0001.png",
            "https://patentimages.storage.googleapis.com/23/9f/00/2b7af374eebdca/imgf000031_0001.png",
            "https://patentimages.storage.googleapis.com/50/17/28/2a3ae26ed3ecbe/imgf000032_0001.png",
            "https://patentimages.storage.googleapis.com/56/21/34/a8e2673a32e4a8/imgf000033_0001.png",
            "https://patentimages.storage.googleapis.com/a1/04/df/c5538e769fc8ea/imgf000034_0001.png",
            "https://patentimages.storage.googleapis.com/35/8a/99/7e42701ab8cdd3/imgf000035_0001.png",
            "https://patentimages.storage.googleapis.com/e2/19/a8/f16edd88712e8e/imgf000036_0001.png",
            "https://patentimages.storage.googleapis.com/1a/83/dd/ed20c160b6604e/imgf000037_0001.png",
            "https://patentimages.storage.googleapis.com/cf/c7/c1/19fbf31fca74e6/imgf000038_0001.png",
            "https://patentimages.storage.googleapis.com/8c/82/28/c38868e7af37be/imgf000039_0001.png",
            "https://patentimages.storage.googleapis.com/62/66/f7/f3ddee4a79683a/imgf000040_0001.png",
            "https://patentimages.storage.googleapis.com/b9/39/12/6398ae8aeea98d/imgf000041_0001.png",
            "https://patentimages.storage.googleapis.com/8f/6c/13/93f03489cf9717/imgf000042_0001.png",
            "https://patentimages.storage.googleapis.com/5b/b3/5d/4c05ed43fbba77/imgf000043_0001.png",
            "https://patentimages.storage.googleapis.com/c1/a6/49/6e39626c0c3e49/imgf000044_0001.png",
            "https://patentimages.storage.googleapis.com/42/2b/b5/bccee7dd280f5d/imgf000045_0001.png",
            "https://patentimages.storage.googleapis.com/3e/69/e2/7f3e14bfdacda2/imgf000046_0001.png",
            "https://patentimages.storage.googleapis.com/af/99/6a/8aa2b993488660/imgf000047_0001.png",
            "https://patentimages.storage.googleapis.com/04/9e/4a/4983ecd624e8b6/imgf000048_0001.png",
            "https://patentimages.storage.googleapis.com/5b/6a/17/de2cd9c47afe01/imgf000049_0001.png",
            "https://patentimages.storage.googleapis.com/a3/8a/ed/007a48dafdc20e/imgf000050_0001.png",
            "https://patentimages.storage.googleapis.com/3a/c7/07/d5e945fdc64c45/imgf000051_0001.png",
            "https://patentimages.storage.googleapis.com/20/00/c6/068e4cc220a0ee/imgf000052_0001.png",
            "https://patentimages.storage.googleapis.com/ab/e4/ab/e6eff3a392e0f4/imgf000053_0001.png",
            "https://patentimages.storage.googleapis.com/6d/4a/27/e2fb2c49a7037c/imgf000053_0002.png",
            "https://patentimages.storage.googleapis.com/1e/36/b8/e010a33f1fa5c4/imgf000053_0003.png",
            "https://patentimages.storage.googleapis.com/e9/cb/94/35e07dfb0ffd04/imgf000053_0004.png",
            "https://patentimages.storage.googleapis.com/b6/41/30/f73b27cbc849f3/imgf000054_0001.png",
            "https://patentimages.storage.googleapis.com/db/0d/90/2d1e6c9c3d3d9d/imgf000054_0002.png",
            "https://patentimages.storage.googleapis.com/65/95/e8/53d018a77daf87/imgf000054_0003.png",
            "https://patentimages.storage.googleapis.com/80/2e/40/5a0f650dff9dd4/imgf000054_0004.png",
            "https://patentimages.storage.googleapis.com/92/4d/72/b31513303e2c16/imgf000055_0001.png",
            "https://patentimages.storage.googleapis.com/4a/64/fe/077a1a0f38ad4e/imgf000055_0002.png",
            "https://patentimages.storage.googleapis.com/05/14/39/1e9229e9a6c7be/imgf000055_0003.png",
            "https://patentimages.storage.googleapis.com/6a/0c/03/5dbb9fba2fc44b/imgf000055_0004.png",
            "https://patentimages.storage.googleapis.com/01/39/e5/4e5af4e527fd91/imgf000056_0001.png",
            "https://patentimages.storage.googleapis.com/06/54/8c/4261e04a6ac049/imgf000057_0001.png",
            "https://patentimages.storage.googleapis.com/39/c4/e9/6391452f3f47f6/imgf000058_0001.png",
            "https://patentimages.storage.googleapis.com/78/19/75/5c208b7129ce4d/imgf000059_0001.png",
            "https://patentimages.storage.googleapis.com/82/70/7a/5652d0f5768098/imgf000060_0001.png",
            "https://patentimages.storage.googleapis.com/a4/3c/68/e784ccd7f260a5/imgf000061_0001.png",
            "https://patentimages.storage.googleapis.com/fe/e7/cf/236035e2c9ca23/imgf000063_0001.png",
            "https://patentimages.storage.googleapis.com/c2/d8/4b/25df08ba60e1ce/imgf000064_0001.png",
            "https://patentimages.storage.googleapis.com/08/64/83/28023a052f1baf/imgf000065_0001.png",
            "https://patentimages.storage.googleapis.com/96/5a/01/5def5525ca97ab/imgf000065_0002.png",
            "https://patentimages.storage.googleapis.com/0e/a5/67/ad8f9db2a77444/imgf000065_0003.png",
            "https://patentimages.storage.googleapis.com/b7/3e/e0/dc9aa48524d4b8/imgf000066_0001.png",
            "https://patentimages.storage.googleapis.com/72/31/38/72da82199f9d83/imgf000067_0001.png",
            "https://patentimages.storage.googleapis.com/3e/0d/9d/5e69a48b89c611/imgf000068_0001.png",
            "https://patentimages.storage.googleapis.com/47/d2/74/fd4a86c3207d49/imgf000068_0002.png",
            "https://patentimages.storage.googleapis.com/01/37/9c/4a84eb1aecb428/imgf000069_0001.png",
            "https://patentimages.storage.googleapis.com/7c/c4/45/10886ca0607064/imgf000069_0002.png",
            "https://patentimages.storage.googleapis.com/8b/aa/dc/8dc00bdcb7b75b/imgf000069_0003.png",
            "https://patentimages.storage.googleapis.com/e3/50/a1/181bdad00f99db/imgf000077_0001.png",
            "https://patentimages.storage.googleapis.com/f2/62/5e/25274130b0f40a/imgf000084_0001.png",
            "https://patentimages.storage.googleapis.com/86/73/00/f1a9d86e96f281/imgf000110_0001.png",
            "https://patentimages.storage.googleapis.com/e5/4f/d1/2be293bb5b2edd/imgf000111_0001.png",
            "https://patentimages.storage.googleapis.com/f1/b6/23/09b5a0c5bd5f10/imgf000111_0002.png",
            "https://patentimages.storage.googleapis.com/7a/2c/12/7ce3ed76e0b7a6/imgf000114_0001.png",
            "https://patentimages.storage.googleapis.com/3b/6a/44/c411758e86ef7c/imgf000117_0001.png",
            "https://patentimages.storage.googleapis.com/d6/67/0c/d38f0ca540275a/imgf000117_0002.png",
            "https://patentimages.storage.googleapis.com/93/e6/8e/cc0b4bae0a1e9c/imgf000117_0003.png",
            "https://patentimages.storage.googleapis.com/6e/aa/dd/548acdd39d7ffd/imgf000118_0001.png",
            "https://patentimages.storage.googleapis.com/c7/8d/e7/0b1fb485db65f5/imgf000119_0001.png",
            "https://patentimages.storage.googleapis.com/95/37/43/c19b09a2a82b9a/imgf000119_0002.png"
        ],
        "movies": [],
        "keywords": [],
        "meta_keywords": [
            ""
        ],
        "tags": null,
        "authors": [],
        "publish_date": "2017-06-16T00:00:00",
        "summary": "",
        "meta_description": "Mesoionic imidazolium compounds of formula (I) and their uses for combating animal pests. The present invention relates to compounds of formula (I), wherein W, T, R1, R2 and R3 are defined as in the description, and to the stereoisomers, salts, tautomers and N-oxides thereof and to compositions comprising such compounds. The invention also relates to methods and uses of these compounds and of compositions thereof, for combating and controlling animal pests. Furthermore the invention relates also to pesticidal methods of applying such substituted pyrimidinium compounds.",
        "meta_lang": "en",
        "meta_favicon": "",
        "meta_site_name": "",
        "canonical_link": "https://patents.google.com/patent/WO2018229202A1/en",
        "text": "Mesoionic imidazolium compounds and derivatives for combating animal pests\n\nThe present invention relates to insecticidal substituted imidazolium compounds and/or to the compositions comprising such compounds for combating invertebrate pests. The invention also relates to pesticidal methods, to uses and to applications of substituted imidazolium compounds as described in the present invention and the stereoisomers, salts, tautomers and N-oxides thereof as well as compositions comprising them.\n\nInvertebrate pests and in particular insects, arthropods and nematodes destroy growing and harvested crops and attack wooden dwelling and commercial structures, thereby causing large economic loss to the food supply and to property. While a large number of pesticidal agents are known, due to the ability of target pests to develop resistance to said agents, there is an ongoing need for new agents for combating invertebrate pests such as insects, arachnids and nematodes. It is therefore an object of the present invention to provide compounds having a good pesticidal activity and showing a broad activity spectrum against a large number of different invertebrate pests, especially against difficult to control insects, arachnids and nematodes.\n\nIt has been found that these objectives can be achieved by compounds of the general formula (I), as defined below, including their stereoisomers, their salts, in particular their agriculturally or veterinary acceptable salts, their tautomers and their N-oxides.\n\nTherefore, in a first aspect the present invention provides compounds of formula (I)\n\nwherein\n\nW is O, and\n\nT is R5, OR6, -N(R7)(R8) or -N(R7a)-N(R7)(R8);\n\nor\n\nW is S, and\n\nT is -N(R7)(R8) or -N(R7a)-N(R7)(R8);\n\nR1 is N02, CN d-Cs-alkyl, C2-C8-alkenyl, C2-C8-alkynyl, C3-Cio-cycloalkyl, C4-Cio-cycloal- kenyl, Cs-Cn-cycloalkylcycloalkyl or R1 may form a three- to eleven-membered saturated, or partially unsaturated or aromatic carbo-or heterocyclic ring or ring system, which may contain 1 to 4 heteroatoms selected from N(RC)P, O, and S, wherein S may be oxidized, and wherein the aforementioned groups and the carbo- or heterocyclic rings system may be unsubstituted, partially or fully substituted with Ra; or\n\nR1 is C(=0)Rb, C(=0)ORe, NR Rc, C(=0)NRbRc, C(=S)NRbRc, S02NR Rc, OC(=0)Rc, OC(=0)ORe, OC(=0)NRbRe, N(Rc)C(=0)Rc, N(Rc)C(=0)ORe, N(Rc)C(=0)NRbRc, NRcS02R , NRcS02NR Rc, Si(Rd)3, C(=NR )R , C(=NORc)Rc , C(=NNRbRc)Rc, C(=NN(C(=0)R )Rc)Rc, C(=NN(C=0)ORc)(Rc)2, S(=0)0(=NR )qRc or N=CR Rc; R2 and R3 are each independently selected from\n\nd-Ce-alkyl, C2-C8-alkenyl, C2-C8-alkynyl, C3-Cio-cycloalkyl, C4-Ci0-cycloalkenyl, which groups may be unsubstituted, partially or fully substituted with Ra; or C(=0)Rb, C(=0)ORe, NR Rc, C(=0)NRbRc, C(=S)NRbRc; C(=NRC)RC, C(=NORc)Rc , C(=NNR- Rc)Rc, C(=NN(C(=0)R )Rc)Rc C(=NN(C=0)ORc)(Rc)2, or\n\nORc, OC(=0)Rc, OC(=0)ORe, OC(=0)NR Re,\n\nNR Rc, N(Rc)C(=0)Rc, N(Rc)C(=0)ORe, N(Rc)C(=0)NR Rc, NRcS02Rb,\n\nNRcS02NR Rc, N=CRbRc;\n\nS(0)mR , S02NRbRc, or Si(Rd)3, or\n\na three- to eleven-membered saturated, or partially unsaturated or aromatic carbo-or heterocyclic ring or ring system, which may contain 1 to 4 heteroatoms selected from N(Rc)p, O, and S, wherein S may be oxidized, wherein the carbo- or heterocyclic rings system may be unsubstituted, partially or fully substituted with Ra; or\n\nwherein one of R2 and R3 is R4; wherein one of R2 and R3 is substituted with one R4;\n\nor\n\nR2 and R3 form a four- to seven-membered ring, taken together with the carbon and nitrogen of the imidazole ring in formula (I), wherein each remaining ring member is se- lected from carbon atoms and up to 3 heteroatoms independently selected from up to\n\n2 O, up to 2 S, and up to 3 N, wherein up to 2 carbon atom ring members are independently selected from C(=0) and C(=S), and the sulfur atom ring members are independently selected from S(=0)m, wherein each ring member may be substituted with Ra and/or Rc;\n\nwherein the ring is substituted with one R4 ;\n\nR4 is Het or R4a ;\n\nHet is a three- to ten-membered heterocyclic ring or a seven- to eleven-membered heterocyclic ring system, each ring or ring system member selected from carbon atoms and up to 4 heteroatoms independently selected from up to 2 O, up to 2 S, and up to\n\n4 N(RC)P, wherein up to 3 carbon atom ring members are independently selected from C(=0) and C(=S) and the sulfur atom ring members are independently selected from each ring or ring system optionally substituted with up to 5 Ra;\n\no, q are each independently 0, 1 or 2, provided that the sum (o + q) is 0, 1 or 2 for each ring;\n\nR4a is Ci-C4-alkyl, Ci-C4-haloalkyl, C2-C -alkenyl, C2-C -haloalkenyl, C2-C -alkynyl, C2-C - haloalkynyl, C3-C7-cycloalkyl, C3-C7-halocycloalkyl, C -C8-alkylcycloalkyl, C -C8- haloalkylcycloalkyl, C4-C8-cycloalkylalkyl, C4-C8-halocycloalkylalkyl, Ci-C6-alkoxy, Ci- C6-haloalkoxy, C2-C6-alkylcarbonyl, C2-C6-haloalkylcarbonyl, CN;\n\neach optionally substituted with one or more substituents selected from CN, ORc,\n\nNR Rc, N02, C(=0)(0)pRc, OC(=0)(0)pRe, C(=0)NR Rc, OC(=0)NR Re,\n\nNRbC(=0)(0)PRe , NRbC(=0)NR Rc, C(=S)NRbRc, S(0)mR , S02NR Rc, OS02Rc, OS02NR Rc, NR S02Rc, NR S02NR Rc, SF5, OCN, SCN, Si(Rd)3, C(=N(0)PR )Rb, C(=NNRbRc)Rb, C(=NN(C(=0)0PRc)R )R , ON=CRbRc, ONR Rc, S(=O)0(=NRb)qRc, S02NR (=0)NRbRc, P(=W)R Rc, OP(=W)(0PRc)R , OP(=W)(ORc)2, N=CR Rc, NR N=CR Rc, NRbNR Rc, NR C(=S)NR Rc , NR C(=NR )NR Rc, NR \"\n\nNRbC(=W)NR Rc, NR NR S02NRbRc, or N=S(=0)PRcRc, or\n\ntwo geminally bound groups R4a together may form a group selected from =0, =S, =CRbRc, =NRC, =NORc, and =NNRCRC ; or R4a is phenyl optionally substituted with one or more substituents selected from halogen, CN, ORc, NR Rc, N02, C(=0)(0)pRc, OC(=0)(0)pRe, C(=0)NRbRc, OC(=0)NRbRe, NR C(=0)(0)PRe , NRbC(=0)NRbRc, C(=S)NR Rc, S(0)mRb, S02NRbRc, OS02Rc, OS02NR Rc, NR S02Rc, NRbS02NRbRc, SF5, OCN, SCN, Si(Rd)3, C(=N(0)PRb)Rb, C(=NNR Rc)R , C(=NN(C(=0)0PRc)R )R , ON=CRbRc, ONRbRc, S(=0)0(=NR )qRc, S02NRb(=0)NR Rc, P(=W)R Rc, OP(=W)(0PRc)R , OP(=W)(ORc)2, N=CRbRc, NR N=CR Rc, NRbNR Rc, NRbC(=S)NR Rc , NR C(=NRb)NR Rc, NR \"\n\nNRbC(=W)NR Rc, NRbNRbS02NRbRc, or N=S(=0)PRcRc,\n\nor R4a is phenyl optionally substituted with one or more substituents selected from Ci- C4-alkyl, Ci-C4-haloalkyl, C2-C4-alkenyl, C2-C4-haloalkenyl, C2-C4-alkynyl, C2-C - haloalkynyl, C3-C7-cycloalkyl, C3-C7-halocycloalkyl, C4-C8-alkylcycloalkyl, C4-Cs- haloalkylcycloalkyl, C4-C8-cycloalkylalkyl, C4-C8-halocycloalkylalkyl, Ci-C6-alkoxy, Ci- C6-haloalkoxy, C2-C6-alkylcarbonyl, C2-C6-haloalkylcarbonyl, which groups may optionally be substituted with halogen, CN, ORc, NRbRc, N02, C(=0)(0)pRc,\n\nOC(=0)(0)PRe, C(=0)NRbRc, OC(=0)NRbRe, NRbC(=0)(0)PRe , NRbC(=0)NRbRc, C(=S)NRbRc, S(0)mRb, S02NR Rc, OS02Rc, OS02NR Rc, NR S02Rc, NRbS02NRbRc, SF5, OCN, SCN, Si(Rd)3, C(=N(0)pR )R , C(=NNRbRc)R , C(=NN(C(=0)OpRc)R )R , ON=CR Rc, ONRbRc, S(=0)0(=NR )qRc, S02NR (=0)NRbRc, P(=W)R Rc,\n\nOP(=W)(0PRc)Rb, OP(=W)(ORc)2, N=CRbRc, NRbN=CRbRc, NRbNRbRc,\n\nNRbC(=S)NR Rc , NRbC(=NRb)NR Rc, NR NR C(=W)NR Rc, NR NRbS02NR Rc, or N=S(=0)PRcRc,\n\nRa is each independently halogen, Ci-C6-alkyl, Ci-C6-haloalkyl, Ci-C6-alkoxy, C1-C6- haloalkoxy, C2-C -alkenyl, C2-C -alkynyl, C3-C6-cycloalkyl, CN, ORc, NRbRc, N02,\n\nC(=0)(0)PRc, OC(=0)(0)PRe, C(=0)NRbRc, OC(=0)NR Re, NR C(=0)(0)PRe , NRbC(=0)NRbRc, C(=S)NRbRc, S(0)mRb, S02NRbRc, OS02Rc, OS02NRbRc,\n\nNRbS02Rc, NRbS02NR Rc, N=S(=0)PRcRc, S(=0)Q(=NRb)qRc, SF5, OCN, SCN, Si(Rd)3 or a three- to six-membered saturated, or partially unsaturated or aromatic carbo- or heterocyclic ring, which may contain 1 to 3 heteroatoms selected from N-(RC)P, O, and\n\nS which may be oxidized, and wherein the aforementioned groups and the carbo- or heterocyclic ring may be partially or fully substituted with Raa, or\n\ntwo geminally bound groups Ra together may form a group selected from =0, =S, =CRbRc, =NRC, =NORc, and =NNRCRC;\n\nRaa is each independently halogen, Ci-C6-alkyl, Ci-C6-haloalkyl, Ci-C6-alkoxy or C1-C6- haloalkoxy;\n\nR is each independently hydrogen, Ci-C6-alkyl, Ci-C6-haloalkyl, Ci-C6-alkoxy, Ci-Ce- haloalkoxy or a three- to six-membered saturated, or partially unsaturated or aromatic carbo- or heterocyclic ring, which may contain 1 to 3 heteroatoms selected from N(Rc)p, O, and S, wherein S may be oxidized and which carbo- or heterocyclic ring may be partially or fully substituted with Raa;\n\nRc is each independently hydrogen, Ci-C4-alkyl, Ci-C4-haloalkyl, Ci-C4-alkylcarbonyl, Ci- C6 cycloalkyi, or a three- to six-membered saturated, partially unsaturated or aromatic carbo- or heterocyclic ring, which may contain 1 to 3 heteroatoms selected from\n\nN(Raa)p, O and S, wherein S may be oxidized and wherein the carbo- or heterocyclic ring may be partially or fully substituted with Raa;\n\nwherein two geminally bound groups R R , RcRb or RCRC together with the atom to which they are bound, may form a 3-, 4-, 5-, 6- or 7- membered saturated, partially un- saturated or aromatic carbo- or heterocyclic ring, which may contain 1 to 2 heteroatoms or heteroatoms groups selected from N, O, S, NO, SO and SO2 and wherein the carbo- or heterocyclic ring may be partially or fully substituted with Ra;\n\nRd is each independently hydrogen, phenyl, Ci-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, C3- Ce-cycloalkyl, or Ci-C6-alkoxyalkyl, wherein the above mentioned groups may be sub- stituted with one or more halogen;\n\nR8 is each independently Ci-C4-alkyl, Ci-C4-haloalkyl, Ci-C4-alkylcarbonyl, C1-C6 cycloalkyi, or a three- to six-membered saturated, partially unsaturated or aromatic carbo- or heterocyclic ring, which may contain 1 to 3 heteroatoms selected from N(Raa)p, O and S, wherein S may be oxidized and wherein the carbo- or heterocyclic ring may be par- tially or fully substituted with Raa;\n\nm is 0, 1 , or 2;\n\nn is 0, 1 or 2;\n\np is O or l ;\n\nR5 is hydrogen, Ci-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, which groups may be inde- pendently from each other substituted with one or up to five halogen or with one NO2,\n\nCN, Cs-Ce-cycloalkyl, O-R51, -S(0)q-R52, -N(R53)(R54), -C(=0)N(R53)(R54), -0-C(=0)-R55, -C(=0)-R55, 0-S02-R5S, aryl, hetaryl, heterocyclyl or oxoheterocyclyl,\n\nwherein aryl, hetaryl, heterocyclyl or oxoheterocyclyl may in turn be substituted with one or up to three halogen, N02, CN, Ci-C6-alkyl, C3-C6-cycloalkyl, Ci-C6-haloalkyl, Ci-C6-alkoxy, CrC6-haloalkoxy, C3-Cs-halocycloalkyl, Ci-C6-alkoxy-Ci-C6-alkyl, Ci-\n\nC6-haloalkoxy-Ci-C6-alkyl, Ci-C6-alkoxy-Ci-C6-alkyloxy, cyano-Ci-C6-alkyl, C3-C6-cy- cloalkyl-Ci-Ce-alkyl, C2-C6-alkenyl, C3-C6-alkynyl, Ci-C6-alkylthio, Ci-C6-alkylcarbonyl, C3-C6-cycloalkylcarbonyl, C2-C6-alkenylcarbonyl, CrC6-haloalkylcarbonyl, C1-C6- alkoxycarbonyl, Ci-C6-alkylsulfonyl, Ci-C6-haloalkylsulfonyl, Ci-C6-alkylaminocar- bonyl, di-(Ci-C6)-alkylaminocarbonyl, Ci-C6-alkylcarbonylamino, aryl or hetaryl;\n\nwherein aryl and hetaryl may be substituted with one or more, identical or different, halogen, CN, N02, hydroxy, Ci-C3-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, CrC6-alkoxy, Ci-C6-haloalkyl, Ci-C6-haloalkoxy or Ci-C6-alkylthio;\n\nor\n\nR5 is C3-C6-cycloalkyl, C3-C6-heterocyclyl, which groups may be independently from each other substituted with one to three halogen or one CN, Ci-C6-alkyl, Ci-C6-haloalkyl, Ci-C6-alkoxy, Ci-C6-haloalkoxy, Cs-Ce-cycloalkyl, Ci-C6-alkylthio, Ci-C6-alkylsulfinyl, Ci-C6-alkylsulfonyl, aryl, hetaryl, aryl-Ci-C6-alkyl or hetaryl-Ci-C6-alkyl,\n\nwherein aryl, hetaryl, aryl-Ci-C6-alkyl and hetaryl-Ci-C6-alkyl may be substituted with one to three halogen, CN, NO2, Ci-C4-alkyl, Ci-C4-haloalkyl, Ci-C4-alkoxy, C1-C4- haloalkoxy;\n\nor\n\n5 is aryl or hetaryl, which groups may be independently from each other substituted with one to three halogen, NO2, amino, CN, SF5, SCN, Ci-C6-alkylamino, di-(Ci-Ce)- alkylamino, hydroxy, COOH, Ci-C6-alkyl, C3-C6-cycloalkyl, Ci-C6-haloalkyl, Ci-dr alkoxy, Ci-C6-haloalkoxy, C3-C6-halocycloalkyl, C3-C6-halocycloalkyl- Ci-C6-alkyl, Ci- C6-alkoxy-Ci-C6-alkyl, Ci-C6-haloalkoxy-Ci-C6-alkyl, Ci-C6-alkoxy-Ci-C6-alkyloxy, cy- ano-CrCe-alkyl, C3-C6-cycloalkyl-Ci-C6-alkyl, C2-C6-alkenyl, C3-C6-alkynyl, SH, Ci-C6- alkylthio, Ci-C6-alkylcarbonyl, C3-C6-cycloalkylcarbonyl, C2-C6-alkenylcarbonyl, C1-C6- haloalkylcarbonyl, Ci-C6-alkoxycarbonyl, Ci-C6-alkylsulfonyl, Ci-C6-haloalkylsulfonyl, Ci-C6-alkylaminocarbonyl, di-(Ci-C6)-alkylaminocarbonyl, or tri-(Ci-C6-alkyl)-silyl; q is 0, 1 or 2;\n\nR51 is hydrogen, Ci-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, C3-C6-cycloalkyl or C3-C6-heter- ocyclyl, which groups may be independently from each other substituted with one to three halogen or one NO2, CN, Ca-Ce-cycloalkyl, Ci-C6-alkoxy, Ci-C6-haloalkoxy, Ci- C6-alkylthio, Ci-Ce-alkylsulfinyl, Ci-C6-alkylsulfonyl, Ci-C6-alkylcarbonyl, Ci-C6-alkoxy- imino-Ci-C6-alkyl, C3-C6-cycloalkylcarbonyl, C2-C6-alkenylcarbonyl, Ci-C6-haloalkyl- carbonyl, Ci-C6-alkoxycarbonyl, Ci-C6-alkylsulfonyl, Ci-C6-haloalkylsulfonyl, C1-C6- alkylaminocarbonyl, di-(Ci-C6)-alkylaminocarbonyl, aryl or hetaryl, wherein aryl and hetaryl may be substituted with one to three halogen, CN, NO2, Ci-C4-alkyl, C1-C4- haloalkyl, Ci-C4-alkoxy or Ci-C4-haloalkoxy;\n\nor\n\nR51 is aryl or hetaryl, which groups may be independently from each other substituted with one to three halogen, NO2, amino, CN, SF5, SCN, Ci-C6-alkylamino, di-(Ci-Ce)- alkylamino, hydroxy, COOH, Ci-C6-alkyl, C3-C6-cycloalkyl, Ci-C6-haloalkyl, C1-C6- alkoxy, CrC6-haloalkoxy, C3-C6-halocycloalkyl, C3-C6-halocycloalkyl-Ci-C6-alkyl, Ci- C6-alkoxy-CrC6-alkyl, Ci-Ce-haloalkoxy-Ci-CB-alkyl, Ci-C6-alkoxy-Ci-CB-alkyloxy, cy- ano-d-Ce-alkyl, C3-C6-cycloalkyl-Ci-C6-alkyl, C2-C6-alkenyl, C3-C6-alkynyl, SH, Ci-C6- alkylthio, CrC6-alkylcarbonyl, C3-C6-cycloalkylcarbonyl, C2-C6-alkenylcarbonyl, Ci-dr haloalkylcarbonyl, Ci-C6-alkoxycarbonyl, CrC6-alkylsulfonyl, Ci-C6-haloalkylsulfonyl, Ci-Ce-alkylaminocarbonyl, di-(Ci-C6)-alkylaminocarbonyl, or tri-(Ci-C6-alkyl)-silyl; R52 is Ci-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, C3-C6-cycloalkyl or C3-C6-heterocyclyl, which groups may be independently from each other substituted with one to three hal- ogen, NO2, CN, Cs-Ce-cycloalkyl, Ci-Ce-alkoxy, d-Ce-haloalkoxy, d-Ce-alkylthio, Ci-\n\nCe-alkylsulfinyl, Ci-C6-alkylsulfonyl, Ci-C6-alkylcarbonyl, Ci-C6-alkoxyimino-Ci-C6-al- kyl, C3-C6-cycloalkylcarbonyl, C2-C6-alkenylcarbonyl, d-C6-haloalkylcarbonyl, Ci-C6- alkoxycarbonyl, Ci-C6-alkylsulfonyl, Ci-C6-haloalkylsulfonyl, Ci-C6-alkylaminocar- bonyl, di-(Ci-C6)-alkylaminocarbonyl, aryl or hetaryl, wherein aryl and hetaryl may be substituted with one to three halogen, CN, NO2, Ci-d-alkyl, d-d-haloalkyl, C1-C4- alkoxy or Ci-C4-haloalkoxy;\n\nor\n\nR52 is aryl or hetaryl, which groups may be independently from each other substituted with one to three halogen, NO2, amino, CN, SF5, SCN, Ci-dralkylamino, di-(Ci-Ce)- alkylamino, hydroxy, COOH, Ci-C6-alkyl, C3-C6-cycloalkyl, Ci-C6-haloalkyl, C1-C6- alkoxy, CrC6-haloalkoxy, C3-C6-halocycloalkyl, C3-C6-halocycloalkyl-Ci-C6-alkyl, Ci- C6-alkoxy-Ci-C6-alkyl, Ci-C6-haloalkoxy-Ci-C6-alkyl, Ci-C6-alkoxy-Ci-C6-alkyloxy, cy- ano-Ci-C6-alkyl, C3-C6-cycloalkyl-Ci-C6-alkyl, C2-C6-alkenyl, C3-C6-alkynyl, Ci-C3-al- kylthio, CrC6-alkylcarbonyl, C3-C6-cycloalkylcarbonyl, C2-C6-alkenylcarbonyl, C1-C6- haloalkylcarbonyl, Ci-C6-alkoxycarbonyl, CrC6-alkylsulfonyl, Ci-C6-haloalkylsulfonyl, Ci-C6-alkylaminocarbonyl, di-(Ci-C6)-alkylaminocarbonyl, or tri-(Ci-C6-alkyl)-silyl; R53 is hydrogen, Ci-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, C3-C6-cycloalkyl, Ci-C6-alkoxy, Ci-C6-alkoxy-Ci-C6-alkyl, Ci-C6-alkoxycarbonyl, Ci-C6-alkylcarbonyl, aryl, hetaryl, ar- ylcarbonyl or hetarylcarbonyl, wherein aryl and hetaryl may be substituted with one to three halogen, CN, N02, Ci-C4-alkyl, Ci-C4-haloalkyl, Ci-C4-alkoxy or Ci-C4-haloal- koxy;\n\nR54 is hydrogen, Ci-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, C3-C6-cycloalkyl or C3-C6-cyclo- alkyl-Ci-C6-alkyl, which groups may be independently from each other substituted with one to five halogen or one CN, NO2, hydroxy, Ci-C6-alkyl, C3-C6-cycloalkyl, Ci- C6-alkoxy, Ci-C6-haloalkoxy, Ci-C6-alkylthio, Ci-C6-alkylsulfinyl, Ci-C6-alkylsulfonyl, Ci-C6-alkoxycarbonyl, Ci-C6-alkylcarbonyl or tri-(Ci-C6-alkyl)-silyl;\n\nor\n\nR54 is aryl, hetaryl, aryl-Ci-Ce-alkyl or hetaryl-Ci-Ce-alkyl, which groups may be independently from each other substituted with halogen, CN, NO2, hydroxy, amino, C1-C6- alkyl, C3-CB-cycloalkyl, C3-C6-cycloalkylamino, CrC4-alkoxy, Ci-C4-haloalkoxy, C1-C4- alkylthio, Ci-C4-alkylsulfinyl, Ci-C4-alkylsulfonyl, Ci-C4-alkylsulfimino, C2-C6- alkoxycarbonyl or C2-C6-alkylcarbonyl,\n\nor\n\nR53 and R54 are connected through two to six carbon atoms and form a ring, which may comprise an additional atom selected from O, S or N, and which may be substituted with one to four Ci-C2-alkyl, halogen, CN, amino or Ci-C2-alkoxy;\n\nR55 is Ci-C6-alkyl, C3-C6-cycloalkyl, Ci-C6-haloalkyl, C3-C6-halocycloalkyl, C3-C6-cycloal- kyl-Ci-C6-alkyl, C3-C3-halocycloalkyl-Ci-C6-alkyl, cyano-Ci-C6-alkyl, CrC6-alkoxy, Ci- C6-haloalkoxy, CrC6-alkoxy-Ci-C6-alkyl, Ci-C6-haloalkoxy-CrC6-alkyl, aryl, hetaryl, aryl-Ci-C6-alkyl or hetaryl-Ci-C6-alkyl, wherein aryl, hetaryl, aryl-Ci-C6-alkyl and he- taryl-Ci-C6-alkyl, may be substituted with one or more, identical or different, halogen, CN, N02, Ci-Ce-alkyl, C3-C6-cycloalkyl, Ci-C6-haloalkyl, Ci-C6-alkoxy, Ci-C6-haloal- koxy, C3-C6-halocycloalkyl or Ci-C6-alkoxy-Ci-C6-alkyl;\n\nR56 is Ci-Ce-alkyl, C3-C6-cycloalkyl, C3-C6-halocycloalkyl, C3-Ce-cycloalkyl-Ci-Ce-alkyl, C3- C6-halocycloalkyl-Ci-C6-alkyl, cyano-Ci-C6-alkyl, Ci-C6-alkoxy, Ci-C6-haloalkoxy, Ci- C6-alkoxy-Ci-C6-alkyl, Ci-C3-haloalkoxy-Ci-CB-alkyl, aryl, hetaryl or aryl-CrC6-alkyl, wherein aryl, hetaryl and aryl-Ci-C6-alkyl may be substituted with one or more, identical or different, halogen, CN , N02, CrC6-alkyl, C3-C6-cycloalkyl, CrC6-haloalkyl, d- C6-alkoxy, Ci-C6-haloalkoxy, C3-C6-halocycloalkyl or Ci-C6-alkoxy-Ci-C6-alkyl;\n\nRs is Ci-C6-alkyl, C3-C6-cycloalkyl, Ci-C6-haloalkyl, C3-C5-halocycloalkyl, C3-C6-cycloal- kyl-Ci-C6-alkyl, C3-C6-halocycloalkyl-Ci-C6-alkyl, cyano-Ci-C6-alkyl, Ci-C6-alkoxy-Ci- C6-alkyl, Ci-C6-haloalkoxy-Ci-C6-alkyl, aryl, hetaryl, aryl-Ci-C6-alkyl or hetaryl-Ci-C6- alkyl, wherein aryl, hetaryl, aryl-Ci-C6-alkyl and hetaryl-Ci-C6-alkyl, may be substituted with one or more, identical or different, halogen, CN, NO2, Ci-CB-alkyl, C3-C6- cycloalkyl, Ci-C6-haloalkyl, Ci-C6-alkoxy, Ci-C6-haloalkoxy, C3-C6-halocycloalkyl or Ci-C6-alkoxy-Ci-C6-alkyl;\n\n7 is hydrogen, Ci-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, C3-C6-cycloalkyl, Ci-C4-alkoxy\n\nCi-C4-alkoxy-CrC6-alkyl, Ci-C6-alkoxycarbonyl, Ci-C6-alkylcarbonyl;\n\nR7a is hydrogen, Ci-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, C3-C6-cycloalkyl, Ci-C4-alkoxy-\n\nCi-C6-alkyl, Ci-C6-alkoxycarbonyl, Ci-C6-alkylcarbonyl;\n\nR8 is hydrogen, Ci-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, which groups may be inde- pendently from each other substituted with one to five halogen or one CN, NO2, hydroxy, Ci-C6-alkyl, C3-C6-cycloalkyl, Ci-C4-alkoxy, Ci-C4-haloalkoxy, Ci-C4-alkylthio, Ci-C4-alkylsulfinyl, Ci-C4-alkylsulfonyl, Ci-C4-alkylsulfimino, Ci-C4-alkylsulfimino-Ci- C4-alkyl, Ci-C4-alkylsulfimino-C2-C5-alkylcarbonyl, Ci-C4-alkylsulfoximino, Ci-C4-alkyl- sulfoximino-Ci-C4-alkyl, Ci-C4-alkylsulfoximino-C2-C5-alkylcarbonyl, d-Cs-alkoxycar- bonyl, Ci-C6-alkylcarbonyl or C3-C6-trialkylsilyl;\n\nor\n\nR8 is aryl-Ci-C6-alkyl or hetaryl-Ci-C6-alkyl, C3-Ci2-cycloalkyl, C3-Ci2-cycloalkyl-Ci-C6- alkyl or C4-Ci2-bicycloalkyl, which groups may be substituted with halogen, CN, NO2, hydroxy, amino, Ci-Ce-alkyl, C3-C6-cycloalkyl, C3-C6-cycloalkylamino, Ci-C4-alkoxy, Ci-C4-haloalkoxy, Ci-C4-alkylthio, Ci-C4-alkylsulfinyl, Ci-C4-alkylsulfonyl, Ci-C4-alkyl- sulfimino, C2-C6-alkoxycarbonyl or C2-C6-alkylcarbonyl,\n\nor\n\nR8 is a five- to six-membered aromatic or heteroaromatic ring which may be substituted with one or more identical or different substituents, a four- to six-membered partially saturated ring, a saturated heterocyclic ring, or a saturated or aromatic heterobicyclic ring which may comprise one to three heteroatoms from O, S or N and which may be substituted with one or more substituents, wherein the substituents are independently from each other halogen, CN, NO2, hydroxy, amino, Ci-C6-alkyl, C2-C6-alkynyl, C1-C6- haloalkyl, C3-C6-cycloalkyl, C3-C6-cycloalkylamino, Ci-C4-alkoxy, CrC4-haloalkoxy, Ci-C4-alkylthio, Ci-C4-alkylsulfinyl, Ci-C4-alkylsulfonyl, Ci-C4-alkylsulfimino, C2-C6- alkoxycarbonyl or C2-C6-alkylcarbonyl,\n\nor\n\nR7 and R8 are connected through two to six carbon atoms and form a ring, which may comprise an additional atom selected from O, S or N, and which may be substituted with one to four Ci-C2-alkyl, halogen, CN, amino or Ci-C2-alkoxy; or a stereoisomer, tautomer, salt, or N-oxide thereof.\n\nWO2017/093214 describes certain mesoionic imidazolium compounds.\n\nWO2014/167084 describes certain substituted pyrimidinium compounds with heterocyclic sub- stituents for combating invertebrate pests.\n\nThe substituted imidazolium compounds of formula (I) according to the present invention, with their characteristic core and substitution pattern, have not yet been described for pesticidal uses or pesticidal applications in agricultural industry or veterinary practice. The substituted compounds of the formula (I), and their agriculturally acceptable salts are highly active against animal pest, i.e. harmful arthropodes and nematodes, especially against insects and acaridae which are difficult to control by other means.\n\nMoreover, the present invention relates to and includes the following embodiments:\n\n- compositions comprising at least one compound of formula (I) as defined above;\n\nagricultural and veterinary compositions comprising an amount of at least one compound of formula (I) or an enantiomer, diasteromer or salt thereof as defined above;\n\na method for combating invertebrate pests, infestation, or infection by invertebrate pests, which method comprises contacting said pest or its food supply, habitat or breeding grounds with a pesticidally effective amount of at least one compound of formula (I) as defined above or a composition thereof;\n\na method for controlling invertebrate pests, infestation, or infection by invertebrate pests, which method comprises contacting said pest or its food supply, habitat or breeding grounds with a pesticidally effective amount of at least one compound of formula (I) as defined above or a composition comprising at least one compound of formula (I);\n\na method for preventing or protecting against invertebrate pests comprising contacting the invertebrate pests, or their food supply, habitat or breeding grounds with substituted imidazo- lium compounds of the general formula (I) as defined above or a composition comprising at least one compound of formula (I) as defined above or a composition comprising at least one compound of formula (I);\n\na method for protecting crops, plants, plant propagation material and/or growing plants from attack or infestation by invertebrate pests comprising contacting or treating the crops, plants, plant propagation material and growing plants, or soil, material, surface, space, area or water in which the crops, plants, plant propagation material is stored or the plant is growing, with a pesticidally effective amount of at least one compound of formula (I) as defined above or a composition comprising at least one compound of formula (I);\n\na non-therapeutic method method for treating animals infested or infected by parasites or preventing animals of getting infected or infested by parasites or protecting animals against infestation or infection by parasites which comprises orally, topically or parenterally administering or applying to the animals a parasiticidally effective amount of a compound of formula (I) as defined above or a composition comprising at least one compound of formula (I);\n\na method for treating, controlling, preventing or protecting animals against infestation or infection by parasites by administering or applying orally, topically or parenterally to the animals a substituted imidazolium compound of the general formula (I) as defined above or a composi- tion comprising at least one compound of formula (I);\n\nseed comprising a compound of formula (I) as defined above, in an amount of from 0.1 g to 10 kg per 100 kg of seed ;\n\nthe use of the compounds of formula (I) as defined above for protecting growing plants or plant propagation material from attack or infestation by invertebrate pests;\n\n- the use of compounds of formula (I) or the enantiomers, diastereomers or veterinary acceptable salts thereof for combating parasites in and on animals;\n\na process for the preparation of a veterinary composition for treating, controlling, preventing or protecting animals against infestation or infection by parasites which comprises adding a g\n\nparasiticidally effective amount of an compound of formula (I) or the enantiomers, diastere- omers and/or veterinary acceptable salt thereof to a carrier composition suitable for veterinary use;\n\nthe use of a compound of formula (I) or the enantiomers, diastereomers and/or veterinary acceptable salt thereof for the preparation of a medicament for treating, controlling, preventing or protecting animals against infestation or infection by parasites.\n\nAll the compounds of the present invention including if applicable their stereoisomers, their tautomers, their salts or their N-oxides as well as compositions thereof are particularly useful for controlling invertebrate pests, in particular for controlling arthropods and nematodes and especially insects. Therefore, the invention relates to the use of a compound as disclosed in the present invention, for combating or controlling invertebrate pests, in particular invertebrate pests of the group of insects, arachnids or nematodes.\n\nThe term \"compound(s) according to the invention\" or \"compound(s) of formula (I)\" as used in the present invention refers to and comprises the compound(s) as defined herein and/or stereoisomers), salt(s), tautomer(s) or N-oxide(s) thereof. The term \"compound(s) of the present invention\" is to be understood as equivalent to the term \"compound(s) according to the invention\", therefore also comprising stereoisomer(s), salt(s), tautomer(s) or N-oxide(s) of compounds of formula (I).\n\nThe term \"composition(s) according to the invention\" or \"composition(s) of the present invention\" encompasses composition(s) comprising at least one compound of formula (I) according to the invention as defined above, therefore also including a stereoisomer, an agriculturally or veterinary acceptable salt, tautomer or an N-oxide of the compounds of formula (I).\n\nThe compounds of the formula (I) are present in mesomeric forms.\n\nThese forms may be expressed in different isoelectronic formulae, each having the formal positive and negative charges on different atoms (as shown below). The present invention extends to all representative isoelectronic structures of compounds of formula I.\n\nThe compounds of the formula (I) may have one or more centers of chirality, i.e. they are present as mixtures of enantiomers or diastereomers. The invention provides both the single pure enantiomers or pure diastereomers of the compounds of formula (I), and their mixtures and the use according to the invention of the pure enantiomers or pure diastereomers of the compound of formula (I) or its mixtures. Suitable compounds of the formula (I) also include all possible geometrical stereoisomers (cis/trans isomers) and mixtures thereof. Cis/trans isomers may be present with respect to an alkene, carbon-nitrogen double-bond or amide group. The term \"stereoisomers)\" encompasses both optical isomers, such as enantiomers or diastereomers, the latter existing due to more than one center of chirality in the molecule, as well as geometrical isomers (cis/trans isomers). The present invention relates to every possible stereoisomer of the compounds of formula (I), i.e. to single enantiomers or diastereomers, as well as to mixtures thereof.\n\nThe compounds of the present invention may be amorphous or may exist in one or more different crystalline states (polymorphs) or modifications which may have a different macroscopic properties such as stability or show different biological properties such as activities. The present invention includes both amorphous and crystalline compounds of the formula (I), mixtures of different crystalline states or modifications of the respective compound I, as well as amorphous or crystalline salts thereof.\n\nSalts of the compounds of the formula (I) are preferably agriculturally and/or veterinary ac- ceptable salts. They can be formed in a customary method, e.g. by reacting the compound with an acid of the anion in question if the compound of formula (I) has a basic functionality or by reacting an acidic compound of formula (I) with a suitable base.\n\nSuitable agriculturally or veterinary useful salts are especially the salts of those cations or the acid addition salts of those acids whose cations and anions, respectively, do not have any ad- verse effect on the action of the compounds according to the present invention. Suitable cations are in particular the ions of the alkali metals, preferably lithium, sodium and potassium, of the alkaline earth metals, preferably calcium, magnesium and barium, and of the transition metals, preferably manganese, copper, zinc and iron, and also ammonium (NhV) and substituted ammonium in which one to four of the hydrogen atoms are replaced by Ci-C4-alkyl, Ci -C4-hydroxy- alkyl, Ci-C4-alkoxy, Ci-C4-alkoxy-Ci-C4-alkyl, hydroxy-Ci-C4-alkoxy-Ci -C4-alkyl, phenyl or benzyl. Examples of substituted ammonium ions comprise methylammonium, isopropylammonium, dimethylammonium, diisopropylammonium, trimethylammonium, tetramethylammonium, tetrae- thylammonium, tetrabutylammonium, 2-hydroxyethylammonium, 2-(2-hydroxyethoxy)ethyl-am- monium, bis(2-hydroxyethyl)ammonium, benzyltrimethylammonium and benzyltriethylammo- nium, furthermore phosphonium ions, sulfonium ions, preferably tri(Ci-C4-alkyl)sulfonium, and sulfoxonium ions, preferably tri(Ci-C4-alkyl)sulfoxonium.\n\nAnions of useful acid addition salts are primarily chloride, bromide, fluoride, hydrogen sulfate, sulfate, dihydrogen phosphate, hydrogen phosphate, phosphate, nitrate, hydrogen carbonate, carbonate, hexafluorosilicate, hexafluorophosphate, benzoate, and the anions of Ci-C4-alkanoic acids, preferably formate, acetate, propionate and butyrate. They can be formed by reacting the compounds of the formulae I with an acid of the corresponding anion, preferably of hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid or nitric acid.\n\nThe term \"N-oxide\" includes any compound of the present invention which has at least one tertiary nitrogen atom that is oxidized to an N-oxide moiety.\n\nThe organic moieties groups mentioned in the above definitions of the variables are - like the term halogen - collective terms for individual listings of the individual group members. The prefix Cn-Cm indicates in each case the possible number of carbon atoms in the group.\n\n\"Halogen\" will be taken to mean fluoro, chloro, bromo and iodo.\n\nThe term \"partially or fully halogenated\" will be taken to mean that 1 or more, e.g. 1 , 2, 3, 4 or 5 or all of the hydrogen atoms of a given radical have been replaced by a halogen atom, in particular by fluorine or chlorine.\n\nThe term \"C n\"Cm\" alkyl\" as used herein (and also in C n\"Cm\" alkylamino, d i-Cn-Cm-alkylamino, Cn- Cm-alkylaminocarbonyl, di-(Cn-Cm-alkylamino)carbonyl, Cn-Cm-alkylthio, Cn-Cm-alkylsulfinyl and Cn-Cm-alkylsulfonyl) refers to a branched or unbranched saturated hydrocarbon group having n to m, e.g. 1 to 10 carbon atoms, preferably 1 to 6 carbon atoms, for example methyl, ethyl, propyl, 1-methylethyl, butyl, 1-methylpropyl, 2-methylpropyl, 1 ,1-dimethylethyl, pentyl, 1 -methyl- butyl, 2-methylbutyl, 3-methylbutyl, 2,2-dimethylpropyl, 1-ethylpropyl, hexyl, 1 ,1 -dimethylpropyl, 1 ,2-dimethylpropyl, 1-methylpentyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 1 ,1-dime- thylbutyl, 1 ,2-dimethylbutyl, 1 ,3-dimethylbutyl, 2,2-dimethylbutyl, 2,3-dimethylbutyl, 3,3-dimethyl- butyl, 1-ethylbutyl, 2-ethylbutyl, 1 ,1 ,2-tri methyl propyl, 1 ,2,2-trimethylpropyl, 1-ethyl-1 -methylpro- pyl, 1-ethyl-2-methylpropyl, heptyl, octyl, 2-ethylhexyl, nonyl and decyl and their isomers. Ci-C4- alkyl means for example methyl, ethyl, propyl, 1-methylethyl, butyl, 1-methylpropyl, 2-methylpropyl or 1 ,1-dimethylethyl.\n\nThe term \"Cn-Cm-haloalkyl\" as used herein (and also in Cn-Cm-haloalkylsulfinyl and Cn-Cm- haloalkylsulfonyl) refers to a straight-chain or branched alkyl group having n to m carbon atoms, e.g. 1 to 10 in particular 1 to 6 carbon atoms (as mentioned above), where some or all of the hydrogen atoms in these groups may be replaced by halogen atoms as mentioned above, for example Ci-C4-haloalkyl, such as chloromethyl, bromomethyl, dichloromethyl, trichloromethyl, flu- oromethyl, difluoromethyl, trifluoromethyl, chlorofluoromethyl, dichlorofluoromethyl, chlorodifluo- romethyl, 1-chloroethyl, -bromoethyl, 1-fluoroethyl, 2-fluoroethyl, 2,2-difluoroethyl, 2,2,2-trifluo- roethyl, 2-chloro-2-fluoroethyl, 2-chloro-2,2-difluoroethyl, 2,2-dichloro-2-fluoroethyl, 2,2,2-trichlo- roethyl, pentafluoroethyl and the like. The term Ci-Cio-haloalkyl in particular comprises C1-C2- fluoroalkyl, which is synonym with methyl or ethyl, wherein 1 , 2, 3, 4 or 5 hydrogen atoms are substituted by fluorine atoms, such as fluoromethyl, difluoromethyl, trifluoromethyl, 1-fluoroethyl, 2-fluoroethyl, 2,2-difluoroethyl, 2,2,2-trifluoroethyl and pentafluoromethyl.\n\nSimilarly, \"Cn-Cm-alkoxy\" and \"Cn-Cm-alkylthio\" (or d-Cm-alkylsulfenyl, respectively) refer to straight-chain or branched alkyl groups having n to m carbon atoms, e.g. 1 to 10, in particular 1 to 6 or 1 to 4 carbon atoms (as mentioned above) bonded through oxygen (or sulfur linkages, respectively) at any bond in the alkyl group. Examples include Ci-C4-alkoxy such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butoxy, isobutoxy and tert-butoxy, further Ci-C4-al- kylthio such as methylthio, ethylthio, propylthio, isopropylthio, and n-butylthio.\n\nAccordingly, the terms \"Cn-Cm-haloalkoxy\" and \"Cn-Cm-haloalkylthio\" (or Cn-Cm-haloalkyl- sulfenyl, respectively) refer to straight-chain or branched alkyl groups having n to m carbon at- oms, e.g. 1 to 10, in particular 1 to 6 or 1 to 4 carbon atoms (as mentioned above) bonded through oxygen or sulfur linkages, respectively, at any bond in the alkyl group, where some or all of the hydrogen atoms in these groups may be replaced by halogen atoms as mentioned above, for example Ci-C2-haloalkoxy, such as chloromethoxy, bromomethoxy, dichloromethoxy, trichloromethoxy, fluoromethoxy, difluoromethoxy, trifluoromethoxy, chlorofluoromethoxy, di- chlorofluoromethoxy, chlorodifluoromethoxy, 1 -chloroethoxy, 1-bromoethoxy, 1 -fluoroethoxy, 2- fluoroethoxy, 2,2-difluoroethoxy, 2,2,2-trifluoroethoxy, 2-chloro-2-fluoroethoxy, 2-chloro-2,2- difluoroethoxy, 2,2-dichloro-2-fluoroethoxy, 2,2,2-trichloroethoxy and pentafluoroethoxy, further Ci-C2-haloalkylthio, such as chloromethylthio, bromomethylthio, dichloromethylthio, trichlorome- thylthio, fluoromethylthio, difluoromethylthio, trifluoromethylthio, chlorofluoromethylthio, dichloro- fluoromethylthio, chlorodifluoromethylthio, 1-chloroethylthio, 1-bromoethylthio, 1 -fluoroethylthio, 2-fluoroethylthio, 2,2-difluoroethylthio, 2,2,2-trifluoroethylthio, 2-chloro-2-fluoroethylthio, 2- chloro-2,2-difluoroethylthio, 2,2-dichloro-2-fluoroethylthio, 2,2,2-trichloroethylthio and pentafluo- roethylthio and the like. Similarly the terms Ci-C2-fluoroalkoxy and Ci-C2-fluoroalkylthio refer to Ci-C2-fluoroalkyl which is bound to the remainder of the molecule via an oxygen atom or a sulfur atom, respectively.\n\nThe term \"C2-Cm-alkenyl\" as used herein intends a branched or unbranched unsaturated hydrocarbon group having 2 to m, e.g. 2 to 10 or 2 to 6 carbon atoms and a double bond in any position, such as ethenyl, 1-propenyl, 2-propenyl, 1-methyl-ethenyl, 1 -butenyl, 2-butenyl, 3-bu- tenyl, 1-methyl-1-propenyl, 2-methyl-1-propenyl, 1 -methyl-2-propenyl, 2-methyl-2-propenyl, 1- pentenyl, 2-pentenyl, 3-pentenyl, 4-pentenyl, 1-methyl-1 -butenyl, 2-methyl-1 -butenyl, 3-methyl- 1-butenyl, 1-methyl-2-butenyl, 2-methyl-2-butenyl, 3-methyl-2-butenyl, 1-methyl-3-butenyl, 2- methyl-3-butenyl, 3-methyl-3-butenyl, 1 ,1-dimethyl-2-propenyl, 1 ,2-dimethyl-1-propenyl, 1 ,2-di- methyl-2-propenyl, 1-ethyl-1-propenyl, 1-ethyl-2-propenyl, 1-hexenyl, 2-hexenyl, 3-hexenyl, 4- hexenyl, 5-hexenyl, 1-methyl-1-pentenyl, 2-methyl-1 -pentenyl, 3-methyl-1-pentenyl, 4-methyl-1- pentenyl, 1-methyl-2-pentenyl, 2-methyl-2-pentenyl, 3-methyl-2-pentenyl, 4-methyl-2-pentenyl, 1-methyl-3-pentenyl, 2-methyl-3-pentenyl, 3-methyl-3-pentenyl, 4-methyl-3-pentenyl, 1-methyl- 4-pentenyl, 2-methyl-4-pentenyl, 3-methyl-4-pentenyl, 4-methyl-4-pentenyl, 1 ,1-dimethyl-2-bu- tenyl, 1 ,1-dimethyl-3-butenyl, 1 ,2-dimethyl-1-butenyl, 1 ,2-dimethyl-2-butenyl, 1 ,2-dimethyl-3-bu- tenyl, 1 ,3-dimethyl-1-butenyl, 1 ,3-dimethyl-2-butenyl, 1 ,3-dimethyl-3-butenyl, 2,2-dimethyl-3-bu- tenyl, 2,3-dimethyl-1-butenyl, 2,3-dimethyl-2-butenyl, 2,3-dimethyl-3-butenyl, 3,3-dimethyl-1-bu- tenyl, 3,3-dimethyl-2-butenyl, 1-ethyl-1 -butenyl, 1-ethyl-2-butenyl, 1 -ethyl-3-butenyl, 2-ethyl-1- butenyl, 2-ethyl-2-butenyl, 2-ethyl-3-butenyl, 1 ,1 ,2-trimethyl-2-propenyl, 1 -ethyl-1-methyl-2-pro- penyl, 1-ethyl-2-methyl-1-propenyl and 1 -ethyl-2-methyl-2-propenyl.\n\nThe term \"C2-Cm-alkynyl\" as used herein refers to a branched or unbranched unsaturated hydrocarbon group having 2 to m, e.g. 2 to 10 or 2 to 6 carbon atoms and containing at least one triple bond, such as ethynyl, propynyl, 1-butynyl, 2-butynyl, and the like.\n\nThe term \"Cn-Cm-alkoxy-Cn-Cm-alkyl\" as used herein refers to alkyl having n to m carbon at- oms, e.g. like specific examples mentioned above, wherein one hydrogen atom of the alkyl radical is replaced by an Cn-Cm-alkoxy group; wherein the value of n and m of the alkoxy group are independently chosen from that of the alkyl group.\n\nThe suffix \"-carbonyl\" in a group or \"C(=0)\" denotes in each case that the group is bound to the remainder of the molecule via a carbonyl C=0 group. This is the case e.g. in alkylcarbonyl, haloalkylcarbonyl, aminocarbonyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkoxycarbonyl, haloalkoxycarbonyl.\n\nThe term \"aryl\" as used herein refers to a mono-, bi- or tricyclic aromatic hydrocarbon radical such as phenyl or naphthyl, in particular phenyl (also referred as to C6H5 as subsitituent).\n\nThe term \"ring system\" denotes two or more directly connected rings.\n\nThe term \"C3-Cm-cycloalkyl\" as used herein refers to a monocyclic ring of 3- to m-membered saturated cycloaliphatic radicals, e.g. cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclohep- tyl, cyclooctyl and cyclodecyl.\n\nThe term \"alkylcycloalkyl\" denotes as well as the term \"alkyl which may be substituted with cycloalkyi\" an alkyl group which is substituted with a cycloalkyi ring, wherein alkyl and cycloakyi are as herein defined.\n\nThe term \"cycloalkylalkyl\" denotes as well as the term \"cycloalkyi which may be substituted with alkyl\" a cycloalkyi ring which is substituted with an alkyl group, wherein alkyl and cycloakyi are as herein defined. The term \"alkylcycloalkylalkyl\" denotes as well as the term \"alkylcycloalkyl which may be substituted with alkyl\" an alkylcycloalkyl group which is substituted with an alkyl, wherein alkyl and alkylcycloakyl are as herein defined.\n\nThe term \" C3-Cm-cycloalkenyl\" as used herein refers to a monocyclic ring of 3- to m-mem- bered partially unsaturated cycloaliphatic radicals.\n\nThe term \"cycloalkylcycloalkyl\" denotes as well as the term \"cycloalkyl which may be substituted with cycloalkyl\" a cycloalkyl substitution on another cycloalkyl ring, wherein each cycloalkyl ring independently has from 3 to 7 carbon atom ring members and the cycloalkyls are linked through one single bond or have one common carbon atom. Examples of cycloalkylcycloalkyl include cyclopropylcyclopropyl (e.g. 1 ,1 '-bicyclopropyl-2-yl), cyclohexylcyclohexyl wherein the two rings are linked through one single common carbon atom (e.g. 1 ,1 '-bicyclohexyl-2-yl), cyclo- hexylcyclopentyl wherein the two rings are linked through one single bond (e.g. 4-cyclopentylcy- clohexyl) and their different stereoisomers such as (1 R,2S)-1 , 1 '-bicyclopropyl-2-yl and (1 R,2R)- 1 , 1 '-bicyclopropyl-2-yl.\n\nThe term \"3- to 6-membered carbocyclic ring\" as used herein refers to cyclopropane, cyclobu- tane, cyclopentane and cyclohexane rings.\n\nThe term \"3-, 4-, 5-, 6- or 7-membered saturated, partially unsaturated or aromatic heterocyclic ring which may contain 1 , 2, 3 or 4 heteroatoms\" or \"containing heteroatom groups\", wherein those heteroatom(s) (group(s)) are selected from N (N-substituted groups), O and S (S-substi- tuted groups) as used herein refers to monocyclic radicals, the monocyclic radicals being saturated, partially unsaturated or aromatic (completely unsaturated). The heterocyclic radical may be attached to the remainder of the molecule via a carbon ring member or via a nitrogen ring member.\n\nExamples of 3-, 4-, 5-, 6- or 7-membered saturated heterocyclyl or heterocyclic rings include: oxiranyl, aziridinyl, azetidinyl, 2-tetrahydrofuranyl, 3-tetrahydrofuranyl, 2-tetrahydrothienyl, 3-tet- rahydrothienyl, 2-pyrrolidinyl, 3-pyrrolidinyl, 3-pyrazolidinyl, 4-pyrazolidinyl, 5-pyrazolidinyl, 2- imidazolidinyl, 4-imidazolidinyl, 2-oxazolidinyl, 4-oxazolidinyl, 5-oxazolidinyl, 3-isoxazolidinyl, 4- isoxazolidinyl, 5-isoxazolidinyl, 2-thiazolidinyl, 4-thiazolidinyl, 5-thiazolidinyl, 3-isothiazolidinyl, 4- isothiazolidinyl, 5-isothiazolidinyl, 1 ,2,4-oxadiazolidin-3-yl, 1 ,2,4-oxadiazolidin 5 yl, 1 ,2,4-thiadia- zolidin-3-yl, 1 ,2,4-thiadiazolidin-5-yl, 1 ,2,4-triazolidin-3-yl,-1 ,3,4-oxadiazolidin-2-yl, 1 ,3,4-thiadia- zolidin-2-yl, 1 ,3,4-triazolidin-2-yl, 2-tetrahydropyranyl, 4-tetrahydropyranyl, 1 ,3-dioxan-5-yl, 1 ,4- dioxan-2-yl, 2-piperidinyl, 3-piperidinyl, 4-piperidinyl, 3-hexahydropyridazinyl, 4-hexahydro- pyridazinyl, 2-hexahydropyrimidinyl, 4-hexahydropyrimidinyl, 5-hexahydropyrimidinyl, 2-piperazi- nyl, 1 ,3,5-hexahydrotriazin-2-yl and 1 ,2,4-hexahydrotriazin-3-yl, 2-morpholinyl, 3-morpholinyl, 2- thiomorpholinyl, 3-thiomorpholinyl, 1-oxothiomorpholin-2-yl, 1-oxothiomorpholin-3-yl, 1 ,1 -diox- othiomorpholin-2-yl, 1 ,1 -dioxothiomorpholin-3-yl, hexahydroazepin-1-, -2-, -3- or -4-yl, hexahy- drooxepinyl, hexahydro-1 ,3-diazepinyl, hexahydro-1 ,4-diazepinyl, hexahydro-1 ,3-oxazepinyl, hexahydro- ,4-oxazepinyl, hexahydro-1 ,3-dioxepinyl, hexahydro-1 ,4-dioxepinyl and the like. Examples of 3-, 4-, 5-, 6- or 7-membered partially unsaturated heterocyclyl or heterocyclic rings include: 2,3-dihydrofur-2-yl, 2,3-dihydrofur-3-yl, 2,4-dihydrofur-2-yl, 2,4-dihydrofur-3-yl, 2,3-dihydrothien-2-yl, 2,3-dihydrothien-3-yl, 2,4-dihydrothien-2-yl, 2,4-dihydrothien-3-yl, 2-pyr- rolin-2-yl, 2-pyrrolin-3-yl, 3-pyrrolin-2-yl, 3-pyrrolin-3-yl, 2-isoxazolin-3-yl, 3-isoxazolin-3-yl, 4- isoxazolin 3 yl, 2-isoxazolin-4-yl, 3-isoxazolin-4-yl, 4-isoxazolin-4-yl, 2-isoxazolin-5-yl, 3-isoxa- zolin-5-yl, 4-isoxazolin-5-yl, 2-isothiazolin-3-yl, 3-isothiazolin-3-yl, 4-isothiazolin-3-yl, 2-isothia- zolin-4-yl, 3-isothiazolin-4-yl, 4-isothiazolin-4-yl, 2-isothiazolin-5-yl, 3-isothiazolin-5-yl, 4-isothia- zolin-5-yl, 2,3 dihydropyrazol-1-yl, 2,3-dihydropyrazol-2-yl, 2,3-dihydropyrazol-3-yl, 2,3-dihydro- pyrazol-4-yl, 2,3-dihydropyrazol-5-yl, 3,4-dihydropyrazol-1-yl, 3,4-dihydropyrazol-3-yl, 3,4-dihy- dropyrazol-4-yl, 3,4-dihydropyrazol-5-yl, 4,5-dihydropyrazol-1-yl, 4,5-dihydropyrazol-3-yl, 4,5- dihydropyrazol-4-yl, 4,5-dihydropyrazol-5-yl, 2,3-dihydrooxazol-2-yl, 2,3-dihydrooxazol-3-yl, 2,3- dihydrooxazol-4-yl, 2,3-dihydrooxazol-5-yl, 3,4-dihydrooxazol-2-yl, 3,4-dihydrooxazol-3-yl, 3,4- dihydrooxazol-4-yl, 3,4-dihydrooxazol-5-yl, 3,4-dihydrooxazol-2-yl, 3,4-dihydrooxazol-3-yl, 3,4- dihydrooxazol-4-yl, 2-, 3-, 4-, 5- or 6-di- or tetrahydropyridinyl, 3-di- or tetrahydropyndazinyl, 4- di- or tetrahydropyndazinyl, 2-di- or tetrahydropyrimidinyl, 4-di- or tetrahydropyrimidinyl, 5-di- or tetrahydropyrimidinyl, di- or tetrahydropyrazinyl, 1 ,3, 5-di- or tetrahydrotriazin-2-yl, 1 ,2,4-di- or tetrahydrotriazin-3-yl, 2,3,4,5-tetrahydro[1 H]azepin-1-, -2-, -3-, -4-, -5-, -6- or -7-yl, 3,4,5,6-tetra- hydro[2H]azepin-2-, -3-, -4-, -5-, -6- or -7-yl, 2,3,4,7 tetrahydro[1 H]azepin-1 -, -2-, -3-, -4-, -5-, -6- or -7-yl, 2,3,6,7 tetrahydro[1 H]azepin-1-, -2-, -3-, -4-, -5-, -6- or -7-yl, tetrahydrooxepinyl, such as 2,3,4,5-tetrahydro[1 H]oxepin-2-, -3-, -4-, -5-, -6- or -7-yl, 2,3,4,7 tetrahydro[1 H]oxepin-2-, -3-, -4- , -5-, -6- or -7-yl, 2,3,6,7 tetrahydro[1 H]oxepin-2-, -3-, -4-, -5-, -6- or -7-yl, tetrahydro-1 , 3-diaze- pinyl, tetrahydro-1 ,4-diazepinyl, tetrahydro-1 ,3-oxazepinyl, tetrahydro-1 ,4-oxazepinyl, tetrahy- dro-1 ,3-dioxepinyl and tetrahydro-1 ,4-dioxepinyl.\n\nExamples of 5- or 6-membered aromatic heterocyclic (hetaryl) or heteroaromatic rings are: 2- furyl, 3-furyl, 2-thienyl, 3-thienyl, 2-pyrrolyl, 3-pyrrolyl, 3-pyrazolyl, 4-pyrazolyl, 5-pyrazolyl, 2-ox- azolyl, 4-oxazolyl, 5-oxazolyl, 2-thiazolyl, 4-thiazolyl, 5-thiazolyl, 2-imidazolyl, 4-imidazolyl, 1 ,3,4-triazol-2-yl, 2-pyridinyl, 3-pyridinyl, 4-pyridinyl, 3-pyridazinyl, 4-pyridazinyl, 2-pyrimidinyl, 4- pyrimidinyl, 5-pyrimidinyl and 2-pyrazinyl.\n\nA \"C2-Cm-alkylene\" is divalent branched or preferably unbranched saturated aliphatic chain having 2 to m, e.g. 2 to 7 carbon atoms, for example CH2CH2, -CH(CH3)-, CH2CH2CH2,\n\nCH(CH3)CH2, CH2CH(CH3), CH2CH2CH2CH2, CH2CH2CH2CH2CH2, CH2CH2CH2CH2CH2CH2, and CH2CH2CH2CH2CH2CH2CH2.\n\nEmbodiments and preferred compounds of the present invention for use in pesticidal methods and for insecticidal application purposes are outlined in the following paragraphs.\n\nThe remarks made below concerning preferred embodiments of the variables (substituents) of the compounds according to the invention, especially with respect to their substituents W, T, R1, R2, R3, R4, Het, R a, Ra, Raa, Rb, Rc, Rd, Re, m, n, p, R5, R51, R52, R53, R54, R55, R6, R7, R7a and R8 are valid both on their own and, in particular, in every possible combination with each other and where applicable, the uses, the methods and the compositions according to the invention. In a particular embodiment, the variables of the compounds of formula (I) have the following meanings, these meanings, both on their own and in combination with one another, being particular embodiments of the compounds of the formula (I):\n\nIn one embodiment <W-1 > of the invention, in the compounds of formula (I), W is O, and T is R5. In a further embodiment <W-2> of the invention, W is O, and T is Ci-C6-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, each optionally substituted with with one or up to five halogen or with one NO2, CN, Ca-Ce-cycloalkyl, O-R5 , -S(0)q-R52, -N(R53)(R54).\n\nIn a further embodiment <W-3>, W is O and T is methyl, optionally substituted with halogen, cyano, Ci-C6-alkoxy, Ci-C6-alkylthio, Ci-C6-alkylsulfinyl, Ci-C6-alkylsulfonyl, C3-C6-cycloalkyl. In a further embodiment <W-4>, W is O and T is OR6, wherein R6 is Ci-C6-alkyl, C3-C6-cycloal- kyl, Ci-C6-haloalkyl, optionally substituted with halogen, cyano, Ci-C6-alkoxy, Ci-C6-alkylthio, Ci-C6-alkylsulfinyl, Ci-C6-alkylsulfonyl, C3-C6-cycloalkyl.\n\nIn an embodiment <1 -1 >, R1 is N02, CN, Ci-C8-alkyl, C2-C8-alkenyl, C2-C8-alkynyl, Ci-C6- alkoxy, C3-C6-cycloalkyl, C4-Cio-cycloalkenyl or Cs-Cn-cycloalkylcycloalkyl, wherein the C-atoms of the aforementioned groups may be unsubstituted, or partially or fully substituted with Ra, wherein Ra has the meaning as hereunder described.\n\nIn another embodiment <1-2>, R1 is a three- to ten-membered saturated, or partially saturated or heterocyclic ring system, which may contain 1 to 3 heteroatoms selected from N(RC)P, O, and S, wherein S may be oxidized and which heterocyclic ring may be unsubstituted or substituted with Ra.\n\nIn a further embodiment <1-3>, R1 is Ci-C4-alkyl, C2-C8-alkenyl, Ci-C6-alkoxy, C3-C6-cycloalkyl or C5-Cii-cycloalkylcycloalkyl, wherein the C-atoms of the aforementioned groups may be unsubstituted, or partially or fully substituted with halogen.\n\nIn a further embodiment <1-4>, R1 is Ci-C4-alkyl, C2-C8-alkenyl, C3-C6-cycloalkyl, phenyl or benzyl, wherein the C-atoms of the aforementioned groups may be unsubstituted, or partially or fully substituted with Ra, wherein Ra has the meaning as hereunder described.\n\nIn a further embodiment <1-5>, R1 is Ci-C4-alkyl, C3-C6-cycloalkyl or phenyl, wherein the C- atoms of the aforementioned groups may be unsubstituted, or partially or fully substituted with halogen or Ci-C4-alkyl.\n\nIn a further embodiment <1-6>, R1 is Ci-C4-alkyl, C2-C4-alkenyl, phenyl or benzyl, wherein the c-atoms of the aforementioned groups may be partially or fully substituted with halogen, preferably CI or F.\n\nIn a further embodiment <1-7>, R1 is CrC4-alkyl, C3-C6-cycloalkyl or phenyl, preferably CH3, CH2CH3, CH(CH3)2, cyclopropyl or phenyl.\n\nIn a further embodiment <1-8>, R1 is Ci-C3-alkyl, preferably CH3, CH2CH3 or CH(CH3)2, particularly R1 is CH3, particularly R1 is CH2CH3.\n\nIn a further embodiment <1-9>, R1 is is Ci-C4-alkyl, C3-C6-cycloalkyl, C2-C4-alkenyl, benzyl or phenyl, which groups may be partially or fully substituted with halogen or CrC4-alkyl.\n\nIn an embodiment <2-1 >, R2 and R3 are each independently selected from Ci-C8-alkyl, C2-C8- alkenyl, C2-C8-alkynyl, C3-Cio-cycloalkyl, C4-Cio-cycloalkenyl, which groups may be unsubstituted, partially or fully substituted with Ra. In an embodiment <2-1 a>, R2 and R3 are each independently selected from Ci-C8-alkyl, C2-C8-alkenyl, C2-C8-alkynyl, C3-Ci0-cycloalkyl, C4-Ci0-cy- cloalkenyl, which groups may be unsubstituted, partially or fully substituted with Ra; ORc, OC(=0)Rc, NRbRc, S(0)mRb. In an embodiment <2-1 b>, R2 and R3 are each independently selected from Ci-C8-alkyl, C2-C8-alkenyl, C2-C8-alkynyl, C3-Cio-cycloalkyl, C4-Cio-cycloalkenyl, which groups may be unsubstituted, partially or fully substituted with halogen.\n\nIn an embodiment <2-1 c>, R2 and R3 are each independently selected from Ci-C8-alkyl, C3- Cio-cycloalkyl, which groups may be unsubstituted, partially or fully substituted with halogen. In a further embodiment <2-2>, R2 and R3 are each independently selected from C(=0)Rb, C(=0)ORe, NRbRc, C(=0)NRbRc, C(=S)NRbRc; C(=NRC)RC, C(=NORc)R<\\ C(=NNRbRc)Rc, C(=NN(C(=0)Rb)Rc)Rc C(=NN(C=0)ORc)(Rc)2.\n\nIn a further embodiment <2-3>, R2 and R3 are each independently selected from ORc, OC(=0)Rc, OC(=0)ORe, OC(=0)NR Re. In a further embodiment <2-4>, R2 and R3 are each independently selected from NRbRc, N(Rc)C(=0)Rc, N(Rc)C(=0)ORe, N(Rc)C(=0)NRbRc, NRcS02R , NRcS02NR Rc, N=CRbRc;\n\nIn a further embodiment <2-5>, R2 and R3 are each independently selected from NRbRc, N(Rc)C(=0)Rc, N(Rc)C(=0)ORe.\n\nIn a further embodiment <2-6>, R2 and R3 are each independently selected from S(0)mRb, S02NR Rc,\n\nIn a further embodiment <2-7>, one of R2 and R3 is R4. In a further embodiment <2-7a>, R3 is R4.\n\nIn a further embodiment <2-8>, R3 is substituted with one R4.\n\nIn a further embodiment <2-9>, R2 and R3 form a four- to seven-membered ring, taken together with the carbon and nitrogen of the imidazole ring in formula (I), wherein each remaining ring member is selected from carbon atoms and up to 3 heteroatoms independently selected from up to 2 O, up to 2 S, and up to 3 N, wherein up to 2 carbon atom ring members are independently selected from C(=0) and C(=S), and the sulfur atom ring members are independently selected from S(=0)m, wherein each ring member may be substituted with Ra and/or Rc; wherein the ring is substituted with one R4 .\n\nIn a further embodiment <2-10>, R2 and R3 , together with the nitrogen and the carbon atom of the imidazolium ring, form a five or six membered ring, wherein each remaining ring member is selected from carbon atoms and up to one heteroatoms independently selected from O, S, and N(RC)P, wherein each ring may be substituted with up to one Ra, wherein Ra has the meaning as hereunder described.\n\nIn a further embodiment <2-11 >, R2 and R3 , together with the nitrogen and the carbon atom of the imidazolium ring, form a five membered ring, wherein each remaining ring member is selected from carbon atoms and up to one heteroatoms independently selected from O, S, and\n\nIn a further embodiment <2-12>, R2 and R3 , together with the nitrogen and the carbon atom of the imidazolium ring, form a six membered ring, wherein each remaining ring member is selected from carbon atoms and up to one heteroatoms independently selected from O, S, and\n\nIn a further embodiment <2-13>, R2 and R3 , together with the nitrogen and the carbon atom of the imidazolium ring, form a five or six membered ring resulting in the compounds of formula (II) selected from the group of compounds of formulae 11-1 to 11-16:\n\n(11-1 ) (II-2) (II-3) (II-4)\n\n(11-13) (11-14) (11-15) (11-16) (11-17)\n\nIn a further embodiment, compounds of formula (I) are selected from the group of compounds of formulae II-2, II-4, II-9, 11-12.\n\nIn an embodiment <4-1 >, R4 is Het, and Het is selected from any one of the following ring systems D-1 to D-56:\n\nD-11 D-12 D-13 D\" 4 D-15\n\nD-51 D-52 D-53 D-54 D-55\n\nWherever used in a structure, the following: # denotes the bond to A in formula (I) In a further embodiment Het is selected from any one of the following ring systems:\n\nD-30 D-35 D-36 D-54 D-55 D-56\n\nIn a further embodiment <4-2>, Het is selected from the following rings systems D-2, D-9, D- 2, D-25, D-28, D-29 and D-54:\n\nD-2 D-9 D-22 D-25 D-28 D-29\n\nD-54 D-56\n\nwherein Ra is halogen, Ci-C4-haloalkyl, CiC4-alkoxy or Ci-C4-alkylthio or phenyl; preferably Ra halogen or halomethyl.\n\nIn a further embodiment <4-3>, Het is selected from the following rings systems D-2, D-9, D- 5 and D-56:\n\nwherein Ra is halogen, Ci-C4-haloalkyl, CiC4-alkoxy or Ci-C4-alkylthio or phenyl, preferably halogen or Ci-C4-haloalkyl; more preferably Ra is CI, Br, F or CF3, most preferably Ra is CI or CF3.\n\nIn a further embodiment <4-4>, Het is selected from the following rings systems D-2, D-25 or D-54:\n\nD-2 D-25 D-54\n\nwherein Ra is halogen or Ci-C4-haloalkyl; preferably Ra is CI, Br, F or CF3, most preferably Ra is CI or CF3.\n\nIn another embodiment <4-5>, Het is selected from the following rings systems D-2a, D-2b, D- 2c, D-25, D-25a, preferably D-25a substituted with CI, and D-56a:\n\nwherein Ra are independently from each other selected from CI, Br, F and CF3.\n\nIn another embodiment <4-6>, Het is D-2, preferably D-2b or D-2c, particularly D-2b, wherein Ra is Cl or CF3.\n\nIn another embodiment <4-7>, Het is selected from D-2a, D-25, preferably D-25a substituted with CI, D-9, preferably D-9a or D9b, D-56, preferably D-56a.\n\nIn another embodiment, Het is D-2a.\n\nIn another embodiment, Het is D-25, preferably D-25a substituted with CI.\n\nIn another embodiment, Het is D-9, preferably D-9a or D9b.\n\nIn another embodiment, Het is D-56, preferably D-56a.\n\nIn a further embodiment <4-8>, R4 is R4a, which is Ci-C4-alkyl, Ci-Crhaloalkyl, C2-C4-alkenyl, C2-C4-haloalkenyl, C2-C4-alkynyl, C2-C4-haloalkynyl, C3-C7-cycloalkyl, C3-C7-halocycloalkyl, C4- Cs-alkylcycloalkyl, C4-C8-haloalkylcycloalkyl, C4-C8-cycloalkylalkyl, C4-C8-halocycloalkylalkyl, Ci- C6-alkoxy, Ci-C6-haloalkoxy, C2-C6-alkylcarbonyl, C2-C6-haloalkylcarbonyl, CN; each optionally substituted with one or more substituents selected from Ci-C6-alkyl, Ci-C6-haloalkyl, C1-C6- alkoxy, Ci-C6-haloalkoxy, C2-C4-alkenyl, C2-C4-alkynyl, C3-C6-cycloalkyl, CN, ORc, NRbRc, N02,\n\nIn a further embodiment <4-9>, R4 is Ci-C4-alkyl, Ci-d-haloalkyl, each optionally substituted with one or more substituents selected from CN, NO2.\n\nIn a further embodiment <4-10>, R4 is CH2CH2CN or CH2CN, preferably CH2CH2CN.\n\nIn an embodiment, Ra is halogen, Ci-C6-alkyl, Ci-C6-haloalkyl, Ci-C6-alkoxy, Ci-C6-haloalkoxy, C3-C6-cycloalkyl, CN, ORc, NRbRc, NO2, phenyl, pyridyl, thiazyl, furanyl, pyrimidinyl or thienyl, wherein the C-atoms aforementioned which groups may be unsubstituted or substituted with one or more Raa, wherein Raa is as hereunder defined.\n\nIn a further embodiment, Ra is halogen, Ci-C4-alkyl, Ci-C4-haloalkyl or C3-C6-cycloalkyl.\n\nIn a further embodiment, Ra is halogen, Ci-C4-alkyl, Ci-C4-haloalkyl or C3-C6-cycloalkyl.\n\nIn a further embodiment, Ra is halogen.\n\nIn an embodiment, Ra is halogen, CN, N02, S(0)mR , C(0)Rc, C(0)ORc, C(0)NRbRc,\n\nC(=S)NRbRc, d-Ce-alkyl, C3-C6-cycloalkyl, C2-C6-alkenyl, C2-C6-alkynyl, Ci-C6-alkoxy, C2-C6- alkenyloxy or C2-C6-alkynyloxy, wherein the C-atoms of the aforementioned groups may be unsubstituted, partially or fully substituted with Raa, wherein is as hereunder defined.\n\nIn a further embodiment, Ra is halogen, CN, CrCe-alkyl, C3-C6-cycloalkyl, C2-C6-alkenyl, C2- C6-alkynyl, Ci-C6-alkoxy, C2-C6-alkenyloxy or C2-C6-alkynyloxy, which C-atoms of the aforementioned groups may be unsubstituted, partially or fully substituted with Raa, wherein Raa is as hereunder defined.\n\nIn a further embodiment, Ra is halogen, CN, Ci-Ce-alkyl, C3-C6-cycloalkyl, C2-C6-alkenyl, C2- C6-alkynyl, Ci-C6-alkoxy, C2-C6-alkenyloxy or C2-C6-alkynyloxy, wherein the C-atoms of the aforementioned groups may be unsubstituted, partially or fully substituted with halogen.\n\nIn a further embodiment, Ra is halogen, Ci-C6-haloalkyl or Ci-C6-alkoxy.\n\nIn a further embodiment, Ra is halogen, CN or Ci-C2-haloalkyl.\n\nIn a further embodiment, Ra is halogen or Ci-C2-haloalkyl.\n\nIn an embodiment, Ra is halogen, preferably Br, CI or F, particularly CI.\n\nIn another embodiment, Ra is Ci-C2-haloalkyl, preferably halomethyl such as CHF2 or CF3, particularly CF3.\n\nIn an embodiment, two geminally bound groups Ra together may form a group selected from =0, =S, =CR Rc, =NRC, =NORc, and =NNRCRC;\n\nIn another embodiment, two geminally bound groups Ra together may form a group selected from =CR Rc, =NRC, =NORc, and =NNRCRC;\n\nIn another embodiment, two geminally bound groups Ra together may form a group selected from =0, =S and =N(Ci-C6-alkyl).\n\nIn another embodiment, two geminally bound groups Ra together may form a =N(Ci-C6-alkyl) group.\n\nIn an embodiment, R is hydrogen, Ci-C6-alkyl, Ci-C6-haloalkyl, Ci-C6-alkoxy, Ci-C6-haloal- koxy, phenyl, pyridyl, thiazyl or thienyl, wherein the C-atoms of the aforementioned groups may be substituted with Raa, wherein Raa is as hereunder defined. In a further embodiment, Rb is hydrogen, d-Ce-alkyl, d-Ce-haloalkyl, Ci-C6-alkoxy or Ci-C6-haloalkoxy. In a further embodiment, Rb is hydrogen, Ci-Ce-alkyl or Ci-C6-haloalkyl. In an embodiment, Rb is Ci-C6-alkyl or C1-C6- haloalkyl. In an embodiment, R is H. In an embodiment, Rc is hydrogen, Ci-C4-alkyl, Ci-C4-haloalkyl, Ci-C4-alkylcarbonyl, Ci-C6 cy- cloalkyl, phenyl, pyridyl, thiazyl or thienyl wherein the C-atoms of the aforementioned groups may be substituted with Raa, wherein Raa is as hereunder defined. In a further embodiment, Rc is hydrogen, Ci-C4-alkyl, Ci-C4-haloalkyl, Ci-C4-alkylcarbonyl, or Ci-C6-cycloalkyl. In an embodi- ment, Rc is hydrogen, Ci-C6-alkyl or Ci-C6-haloalkyl. In an embodiment, Rc is Ci-C6-alkyl or Ci- C6-haloalkyl. In an embodiment, Rc is H.\n\nIn an embodiment, two geminally bound groups RbRb, RcR or RCRC together with the atom to which they are bound, may form a 3-, 4-, 5-, 6- or 7- membered saturated, partially unsaturated or aromatic carbo- or heterocyclic ring, which may contain 1 to 2 heteroatoms or heteroa- toms groups selected from N, O, S, NO, SO and SO2 and wherein the carbo- or heterocyclic ring may be partially or fully substituted with Ra.\n\nIn another embodiment, two geminally bound groups RbRb, RcRb or RCRC together with the atom to which they are bound, may form a 5- or 6- membered saturated, partially unsaturated or aromatic carbocyclic ring, which ring may be partially or fully substituted with Ra, and wherein Ra is as hereunder defined.\n\nIn another embodiment, two geminally bound groups RbR , RcR or RCRC together with the atom to which they are bound, may form a 5- or 6- membered saturated, partially unsaturated or aromatic heterocyclic ring, which may contain 1 to 2 heteroatoms or heteroatoms groups selected from N , O, S, NO, SO and SO2, wherein the heterocyclic ring may be partially or fully substituted with Ra, and wherein Ra is as hereunder defined.\n\nIn an embodiment, Rd is hydrogen, phenyl, Ci-C4-alkyl or C2-C6-alkenyl, wherein the aforementioned groups may be substituted with one or more halogen. In a further embodiment, Rd is Ci-C4-alkyl or phenyl, which may be substituted with halogen. In another embodiment, Rc C1-C4- alkyl, preferably CH3.\n\nIn an embodiment, Re is Ci-C4-alkyl, Ci-C4-haloalkyl, Ci-C4-alkylcarbonyl, C1-C6 cycloalkyl, phenyl, pyridyl, thiazyl or thienyl wherein the aforementioned groups may be substituted with Raa, wherein Raa is as hereunder defined. In a further embodiment, Re is Ci-C4-alkyl, C1-C4- haloalkyl, Ci-C4-alkylcarbonyl, or Ci-C6-cycloalkyl. In a further embodiment, Re is Ci-C4-alkyl or Ci-C4-haloalkyl.\n\nIn an embodiment, Raa is halogen, Ci-C6-alkyl or Ci-C6-haloalkyl. In another embodiment, Raa is Ci-C6-alkoxy or Ci-C6-haloalkoxy. In an embodiment, Raa is halogen.\n\nIn an embodiment, R2a is halogen, Ci-C6-haloalkyl, Ci-C6-alkoxy, Ci-C6-haloalkoxy, ORc, C(=0)ORc, C(=0)N RbRc, or phenyl, wherein the C-atoms of the aforementioned groups may be unsubstituted or substituted with one or more R2aa, wherein R2aa is as hereunder defined, partic- ularly R2a is halogen, Ci-C6-alkoxy, or Ci-C6-haloalkoxy.\n\nIn an embodiment, two geminally bound groups R2a together may form a group selected from\n\nIn an embodiment, R2a is halogen, Ci-C6-alkyl, Ci-C6-haloalkyl, Ci-C6-alkoxy, Ci-C6-haloal- koxy, C3-C6-cycloalkyl, CN , ORc, NRbRc, NO2, phenyl, pyridyl, thiazyl, furanyl, pyrimidinyl or thienyl, wherein the C-atoms of the aforementioned groups may be unsubstituted or substituted with one or more R2aa, wherein R2aa is as hereunder defined.\n\nIn a further embodiment, R2a is halogen, Ci-C4-haloalkyl or C3-C6-haloalkoxy.\n\nIn a another embodiment, R2a is phenyl which may be substituted with one or more R2aa. In a another embodiment, R2a is halogen. In another embodiment, R2a is Ci-C6-haloalkyl. In another embodiment, R2a is Ci-C6-haloalkoxy.\n\nIn another embodiment, R2a is halogen, CN, N02, S(0)mR , C(=0)Rc, C(=0)ORc, C(0)NR Rc, C(=S)NRbRc, Ci-Ce-alkyI, C3-C6-cycloalkyl, C2-C6-alkenyl, C2-C6-alkynyl, Ci-C6-alkoxy, C2-C6- alkenyloxy or C2-C6-alkynyloxy, which C-atoms of the aforementioned groups may be unsubsti- tuted, partially or fully substituted with Raa, wherein is as hereunder defined.\n\nIn a further embodiment, R2a is, C(=0)ORc or C(=0)NRbRc.\n\nIn another embodiment, R2a is halogen, CN, Ci-C6-alkyl, C3-C6-cycloalkyl, C2-C6-alkenyl, C2- C6-alkynyl, Ci-C6-alkoxy, C2-C6-alkenyloxy or C2-C6-alkynyloxy, which C-atoms of the aforemen- tioned groups may be unsubstituted, partially or fully substituted with R2aa, wherein R2aa is as hereunder defined.\n\nIn an embodiment, R2a is Br, CI or F, particularly CI.\n\nIn another embodiment, R2a is Ci-C2-haloalkyl, preferably halomethyl such as CHF2 or CF3, particularly CF3.\n\nIn an embodiment, R2aa is halogen, Ci-C6-alkyl, Ci-C6-haloalkyl, Ci-C6-alkoxy, Ci-C6-haloal- koxy, C2-C4-alkenyl, C2-C4-alkynyl, C3-C6-cycloalkyl, CN, N(C C3-alkyl)( Ci-C6-alkyl), C(=0)N(Ci-C6-alkyl)( Ci-C6-alkyl), S(0)m(CrC6-alkyl), S02N(Ci-C6-al- kyl)(Ci-C6-alkyl), OS02(Ci-C6-alkyl), N(Ci-C6-alkyl)S02(Ci-C6-alkyl), or S(=0)P(=N(Ci-C6-al- kyl))(Ci-C6-alkyl) or two geminally bound groups R2aa together may form a group selected from\n\nIn an embodiment, R2aa is halogen, Ci-C6-alkyl, Ci-C6-haloalkyl, Ci-C6-alkoxy, Ci-C6-haloal- koxy, C2-C4-alkenyl, C2-C4-alkynyl, C3-C6-cycloalkyl, CN, N(Ci-C3-alkyl)( Ci-Ce-alkyI),\n\nC(=0)(0)p(Ci-C3-alkyl), C(=0)N(Ci-C6-alkyl)( Ci-C3-alkyl), S(0)m(Ci-C6-alkyl), S02N(Ci-C6-al- kyl)(CrC6-alkyl), OS02(C C6-alkyl), N(Ci-C6-alkyl)S02(Ci-C5-alkyl), or S(=0)p(=N(CrC6-al- kyl))(CrC6-alkyl). In another embodiment, two geminally bound groups R2aa together may form a group selected from =0, =S and =N(Ci-C6-alkyl).\n\nIn an embodiment, compound of formula I is formula II-4, wherein\n\nR1 is alkyl, preferably CH3;\n\nW is O;\n\nT is haloalkyl, preferably -CH2-CI;\n\nR4 is D-25, preferably D-25a substituted with CI;\n\nIn an embodiment, m is 0. In another embodiment, m is 1. In another embodiment, m is 2. In an embodiment, n is 0. In another embodiment, n is 1. In another embodiment, n is 2.\n\nIn an embodiment, p is 0. In another embodiment, p is 1.\n\nPreferred embodiment combinations are as shown in the following table:\n\nTable of embodiment combinations\n\nNo W/T R1 R2 and R3 R4\n\nEC-1 <W-1 > <1 -1 > <2-1 > <4-1 >\n\nEC-2 <W-1 > <1 -1 > <2-1 > <4-2>\n\nEC-3 <W-1 > <1 -1 > <2-1 > <4-3>\n\nEC-4 <W-1 > <1 -1 > <2-1 > <4-4>\n\nEC-5 <W-1 > <1 -1 > <2-1 > <4-5>\n\nEC-6 <W-1 > <1 -1 > <2-1 > <4-6>\n\nIn the same way, the combinations EC-1171 to EC-2340 are part of the invention, wherein <W-2> is used instead of <W-1 >.\n\nIn the same way, the combinations EC-2341 to EC-3510 are part of the invention, wherein <W-3> is used instead of <W-1 >.\n\nIn the same way, the combinations EC-3511 to EC-4680 are part of the invention, wherein <W-2> is used instead of <W-1 >.\n\nIn particular, with a view to their use, preference is given to the compounds of the formula (I) compiled in the tables below, and to the preferred compounds of formula 11-1 , II-2, 11 3 , II-4, II-5, II-6, II-7, and 11-15. Each of the groups mentioned for the substituents in the tables are furthermore per se, independently of the combination in which they are mentioned, a particularly preferred aspect of the substituent in question. Further, each individual meaning of a substituent in the tables constitutes a particularly preferred embodiment of the substituents in question. Table 1 : Compounds of the formula (111-1 ) corresponding to the compounds of the formula 11- . in which the combination of R1 , R4 and T for a compound corresponds in each case to one line of Table A:\n\nTable 2 : Compounds of the formula (II I-2) corresponding to the compounds of the formula II-2, in which the combination of R1 , R4 and T for a compound corresponds in each case to one line of Table A:\n\nTable 3 : Compounds of the formula (III-3) corresponding to the compounds of the formula 113. in which the combination of R1 , R4 and T for a compound corresponds in each case to one line of Table A:\n\nTable 4 : Compounds of the formula (III-4) corresponding to the compounds of the formula II-4, in which the combination of R1 , R4 and T for a compound corresponds in each case to one line of Table A:\n\nTable 5 : Compounds of the formula (II I-5) corresponding to the compounds of the formula II-5, in which the combination of R1 , R4 and T for a compound corresponds in each case to one line of Table A:\n\nTable 6 : Compounds of the formula (111-6) corresponding to the compounds of the formula 11-6, in which the combination of R1 , R4 and T for a compound corresponds in each case to one line of Table A:\n\nTable 7 : Compounds of the formula (IM-7) corresponding to the compounds of the formula II-7, in which the combination of R1 , R4 and T for a compound corresponds in each case to one line of Table A:\n\nTable 8 : Compounds of the formula (III-8) corresponding to the compounds of the formula II-8, in which the combination of R1 , R4 and T for a compound corresponds in each case to one line of Table A:\n\nTable 9 : Compounds of the formula (III-9) corresponding to the compounds of the formula II-9, in which the combination of R1 , R4 and T for a compound corresponds in each case to one line of Table A:\n\nTable 10 : Compounds of the formula (111-10) corresponding to the compounds of the formula 11-10, in which the combination of R1 , R4 and T for a compound corresponds in each case to one line of Table A:\n\nTable 1 1 : Compounds of the formula (111-1 1 ) corresponding to the compounds of the formula 11-15, in which the combination of R1 , R4 and T for a compound corresponds in each case to one line of Table A:\n\nTable 12 : Compounds of the formula (111-12) corresponding to the compounds of the formula 11-17, in which the combination of R1 , R4 and T for a compound corresponds in each case to one line of Table A:\n\nTable A:\n\nNo. T R4 R1\n\nA- CH3 CH3\n\n= D2b.1\n\nA-187 >-NH D2b.1 CH2CH=CH2\n\nA-188 CH3 CH2CH=CH2\n\n= D25a.1\n\nA-189 CH2-CI D25a.1 CH2CH=CH2\n\nA-190 CH2-OCH3 D25a.1 CH2CH=CH2\n\nA-191 CH2-OCH(CH3)2 D25a.1 CH2CH=CH2\n\nA- 192 OCH3 D25a.1 CH2CH=CH2\n\nA-193 CH2-SCH3 D25a.1 CH2CH=CH2\n\nA- 194 CH2-SCH2CH3 D25a.1 CH2CH=CH2\n\nA-195 CH2-S(0)CH2CH3 D25a.1 CH2CH=CH2\n\nA-196 CH2-N HCH3 D25a.1 CH2CH=CH2\n\nA-197 CH2-NHCH2CH3 D25a.1 CH2CH=CH2\n\nA-198 C^NH D25a.1 CH2CH=CH2\n\nA-199 CH3 CH2CH=CH2\n\n= D9b\n\nA-200 CH2-CI D9b CH2CH=CH2\n\nA-201 CH2-OCH3 D9b CH2CH=CH2\n\nA-202 CH2-OCH(CH3)2 D9b CH2CH=CH2\n\nA-203 OCH3 D9b CH2CH=CH2\n\nA-204 CH2-SCH3 D9b CH2CH=CH2\n\nA-205 CH2-SCH2CH3 D9b CH2CI- CH2\n\nA-206 CH2-S(0)CH2CH3 D9b CH2CH=CH2\n\nA-207 CH2-N HCH3 D9b CH2CH=CH2\n\nA-208 CH2-NHCH2CH3 D9b CH2CH=CH2\n\nA-209 >-NH D9b CH2CH=CH2\n\nA-210 CH3 CH2CH2-CN CH2CH=CH2\n\nA-21 1 CH2-CI CH2CH2-CN CH2CH=CH2\n\nA-212 CH2-OCH3 CH2CH2-CN CH2CH=CH2\n\nA-213 CH2-OCH(CH3)2 CH2CH2-CN CH2CH=CH2\n\nA-214 OCH3 CH2CH2-CN CH2CH=CH2\n\nA-215 CH2-SCH3 CH2CH2-CN CH2CH=CH2\n\nA-216 CH2-SCH2CH3 CH2CH2-CN CH2CH=CH2\n\nA-217 CH2-S(0)CH2CH3 CH2CH2-CN CH2CH=CH2\n\nThe compound of formula (I) according to the present invention can be prepared according to the following syntheses routes, e.g. according to the preparation methods and preparation schemes as described below.\n\nThe compounds of formula (I) according to the present invention can be prepared analogously to the methods described in WO2014/167084 and WO2017/093214, in particular according to the preparation methods and preparation schemes as described e.g. below.\n\nThe compounds used as starting materials for the syntheses of the compounds according to the present invention can generally be prepared by standard methods of organic chemistry. If not otherwise specified, the definitions of the variables such as R1, R2 and R3 of the structures given in the schemes have the same meaning as defined above.\n\nCompounds of the formula (la) can for example be prepared by reacting the appropriately substituted compounds P-1 with halogenated ketones or acid anhydrides P-2, wherein is Br, CI, or -0-C(=0)CH2-hal, and hal is preferably Br or CI, analogously to methods described in the literature (see, for example, Canadian Journal of Chemistry (1971 ), 49 (4), 668-671). Scheme 1\n\n(la)\n\nP-1 P-2\n\nCompounds of type P-1 are known in the literature (see, for example, WO2009099929, WO2012092115, WO201 1057022, WO201 1017342) or can be prepared in analogy to literature known procedures. Compounds like P-2 are commercially available.\n\nCompounds of the formula (lb), where Alk is C1-C4 alkyl group, can be synthesized from P-1 , by reacting with e.g. 2-chloromalonicmonoester monochloride like P-3 in the presence of base, for example, triethylamine.\n\nScheme 2\n\nP\"1 (lb)\n\nCompounds of type P-3 are known in the literature or can be prepared in analogy to literature known procedures (e.g. Tetrahedron 1993, 49, 9447-9452).\n\nCompounds of the formula (Ic) can be obtained by reacting esters of type (lb) with amino compounds P-4. For some amines, activation reagents like, for example, trimethylaluminium, can be applied.\n\nSche\n\n(lb) (Ic) Amine compounds of type P-4 are commercially available or known in the literature. Compounds of formula (Id) can be prepared by reacting compounds of type (la) with alcoholates or alcohols in the presence of base, like, for example sodium hydride, as shown in Scheme 4. Compounds like (Id) can be transformed to compounds like (le) using known methods with compounds like P-5, where Li is CI, Br or -0(=0)R55 in the presence of base, like, for example, tri- ethylamine.\n\nScheme 4\n\nThe alcohols and compounds of type P-5 are commercially available or known in the literature. Compounds of formula (If) can be obtained from the compounds (la) via reaction with thiolates or thioles in the presence of base, like, for example, sodium hydride, as shown in Scheme 5. Using known methods, compounds of formula (If) can be further oxidized in the presence of oxidation agent, like, for example /77-chloroperoxybenzoic acid, to sulfoxides and sulfones.\n\nR3\n\n(ig)\n\nCompounds of type P-6 are commercially available or known in the literature.\n\nCompounds of formula (Ih) can be prepared from compounds of formula (la) via reaction with amino compounds like P-7 using known methods in the presence of base, like, for example, tri- ethylamine, as shown in Scheme 6. In the same manner, other amino compounds, like, for example, hydrazine could be used as well. Subsequently, compounds of formula (Ih) where L1 is CI, Br or -0(=0) R55, can react with carboxylic acid halides or carboxylic acid anhydride like P-8 in the presence of base, like, for example, triethylamine, providing compounds of formula (li).\n\nScheme 6\n\nCompounds of type P-7 and P-8 are commercially available or known in the literature.\n\nCompounds of formula (Ij) can be obtained via dehalogenation reaction of compounds of formula (la) using activated zinc as shown in Scheme 7 (see, for example, Dyes and Pigments 2013, 96, 7-15).\n\nScheme 7\n\nCompounds of formula (Im) can be prepared from compounds of formula (Ic) in analogy to known methods as shown in Scheme 8, using sulphurising agents, like, for example, P2S5 or Lawesson's reagent. Scheme 8\n\nCompounds of formula (Ik) can be prepared via compounds of formula II in analogy to the reaction showed in Scheme 3. Corresponding ester compounds of formula (lb) can react with N,0- dimethylaminohydroxylamine P-9, providing a \"Weinreb-Amide\" of formula (li). Compounds of formula (li) can further react with oraganometallic compounds of formla P-10, for example, alkyl- or aryllithium compounds or Grignard reagents (see, for example, WO201 154844, WO2005100301 ) to provide desired compounds of formula (Ik) as shown in Scheme 9.\n\nScheme 9\n\nAmine compounds P-1 , can also undergo reaction with carboxylic acid chlorides of type P-1 1 in the presence of base, in analogy to Scheme 2, providing compounds of formula (Ik) as shown in\n\nSchemel O.\n\nCompounds of type P-1 1 are either known in the literature or can be obtained from corre- sponding carboxylic acids (see, for example, EP 37015, DE4301356, JP2006232788).\n\nSchemelO\n\nIf individual compounds cannot be prepared via the above described routes, they can be prepared by derivatization of other compounds of formula (I) or by customary modifications of the synthesis routes described.\n\nFor example, in individual cases, certain compounds of formula (I) can advantageously be pre- pared from other compounds of formula (I) by derivatization, e.g. by ester hydrolysis, amidation, esterifi cation, ether cleavage, olefination, reduction, oxidation and the like, or by customary modifications of the synthesis routes described.\n\nThe reaction mixtures are worked up in the customary manner, for example by mixing with water, separating the phases, and, if appropriate, purifying the crude products by chromatography, for example on alumina or silica gel.\n\nAs used herein, the term \"compound(s) of the present invention\" or \"compound(s) according to the invention\" refers to the compound(s) of formula (I) as defined above, which are also referred to as \"compound(s) of formula I\" or \"compound(s) I\" or \"formula I compound(s)\", and includes their salts, tautomers, stereoisomers, and N-oxides.\n\nMixtures\n\nThe present invention also relates to a mixture of at least one compound of the present invention with at least one mixing partner as defined herein after. Preferred are binary mixtures of one compound of the present invention as component I with one mixing partner as defined herein after as component II. Preferred weight ratios for such binary mixtures are from 5000:1 to 1 :5000, preferably from 1000:1 to 1 :1000, more preferably from 100:1 to 1 :100, particularly preferably from 10:1 to 1 :10. In such binary mixtures, components I and II may be used in equal amounts, or an excess of component I, or an excess of component II may be used.\n\nMixing partners can be selected from pesticides, in particular insecticides, nematicides, and acaricides, fungicides, herbicides, plant growth regulators, fertilizers, and the like. Preferred mixing partners are insecticides, nematicides and fungicides.\n\nThe following list M of pesticides, grouped and numbered according the Mode of Action Classification of the Insecticide Resistance Action Committee (IRAC), together with which the compounds of the present invention can be used and with which potential synergistic effects might be produced, is intended to illustrate the possible combinations, but not to impose any limitation: M.1 Acetylcholine esterase (AChE) inhibitors from the class of: M.1A carbamates, for example aldicarb, alanycarb, bendiocarb, benfuracarb, butocarboxim, butoxycarboxim, carbaryl, carbofu- ran, carbosulfan, ethiofencarb, fenobucarb, formetanate, furathiocarb, isoprocarb, methiocarb, methomyl, metolcarb, oxamyl, pirimicarb, propoxur, thiodicarb, thiofanox, trimethacarb, XMC, xylylcarb and triazamate; or from the class of M.1 B organophosphates, for example acephate, azamethiphos, azinphos-ethyl, azinphosmethyl, cadusafos, chlorethoxyfos, chlorfenvinphos, chlormephos, chlorpyrifos, chlorpyrifos-methyl, coumaphos, cyanophos, demeton-S-methyl, dia- zinon, dichlorvos/ DDVP, dicrotophos, dimethoate, dimethylvinphos, disulfoton, EPN, ethion, ethoprophos, famphur, fenamiphos, fenitrothion, fenthion, fosthiazate, heptenophos, imicyafos, isofenphos, isopropyl O- (methoxyaminothio-phosphoryl) salicylate, isoxathion, malathion, me- carbam, methamidophos, methidathion, mevinphos, monocrotophos, naled, omethoate, oxyde- meton-methyl, parathion, parathion-methyl, phenthoate, phorate, phosalone, phosmet, phos- phamidon, phoxim, pirimiphos- methyl, profenofos, propetamphos, prothiofos, pyraclofos, pyri- daphenthion, quinalphos, sulfotep, tebupirimfos, temephos, terbufos, tetrachlorvinphos, thi- ometon, triazophos, trichlorfon and vamidothion;\n\nM.2. GABA-gated chloride channel antagonists such as: M.2A cyclodiene organochlorine com- pounds, as for example endosulfan or chlordane; or M.2B fiproles (phenylpyrazoles), as for example ethiprole, fipronil, flufiprole, pyrafluprole and pyriprole;\n\nM.3 Sodium channel modulators from the class of M.3A pyrethroids, for example acrinathrin, allethrin, d-cis-trans allethrin, d-trans allethrin, bifenthrin, bioallethrin, bioallethrin S-cylclopen- tenyl, bioresmethrin, cycloprothrin, cyfluthrin, beta-cyfluthrin, cyhalothrin, lambda-cyhalothrin, gamma-cyhalothrin, cypermethrin, alpha-cypermethrin, beta-cypermethrin, theta-cypermethrin, zeta-cypermethrin, cyphenothrin, deltamethrin, empenthrin, esfenvalerate, etofenprox, fenpropathrin, fenvalerate, flucythrinate, flumethrin, tau-fluvalinate, halfenprox, heptafluthrin, im- iprothrin, meperfluthrin.metofluthrin, momfluorothrin, permethrin, phenothrin, prallethrin, profluthrin, pyrethrin (pyrethrum), resmethrin, silafluofen, tefluthrin, tetramethylfluthrin, tetrame- thrin, tralomethrin and transfluthrin; or M.3B sodium channel modulators such as DDT or meth- oxychlor;\n\nM.4 Nicotinic acetylcholine receptor agonists (nAChR) from the class of M.4A neonicotinoids, for example acetamiprid, clothianidin, cycloxaprid, dinotefuran, imidacloprid, nitenpyram, thia- cloprid and thiamethoxam; or the compounds M.4A.2: (2E-)-1-[(6-Chloropyridin-3-yl)methyl]-N'- nitro-2-pentylidenehydrazinecarboximidamide; or M4.A.3: 1 -[(6-Chloropyridin-3-yl)methyl]-7-me- thyl-8-nitro-5-propoxy-1 ,2,3,5,6,7-hexahydroimidazo[1 ,2-a]pyridine; or from the class M.4B nicotine;\n\nM.5 Nicotinic acetylcholine receptor allosteric activators from the class of spinosyns, for example spinosad or spinetoram;\n\nM.6 Chloride channel activators from the class of avermectins and milbemycins, for example abamectin, emamectin benzoate, ivermectin, lepimectin or milbemectin;\n\nM.7 Juvenile hormone mimics, such as M.7A juvenile hormone analogues as hydroprene, ki- noprene and methoprene; or others as M.7B fenoxycarb or M.7C pyriproxyfen;\n\nM.8 miscellaneous non-specific (multi-site) inhibitors, for example M.8A alkyl halides as methyl bromide and other alkyl halides, or M.8B chloropicrin, or M.8C sulfuryl fluoride, or M.8D borax, or M.8E tartar emetic;\n\nM.9 Selective homopteran feeding blockers, for example M.9B pymetrozine, or M.9C floni- camid;\n\nM.10 Mite growth inhibitors, for example M.10A clofentezine, hexythiazox and diflovidazin, or M.10B etoxazole;\n\nM.11 Microbial disruptors of insect midgut membranes, for example bacillus thuringiensis or bacillus sphaericus and the insecticdal proteins they produce such as bacillus thuringiensis subs p. israelensis, bacillus sphaericus, bacillus thuringiensis subs p. aizawai, bacillus thuringiensis subsp. kurstaki and bacillus thuringiensis subsp. tenebrionis, or the Bt crop proteins: CrylAb, CrylAc, Cryl Fa, Cry2Ab, mCry3A, Cry3Ab, Cry3Bb and Cry34/35Ab1 ;\n\nM.12 Inhibitors of mitochondrial ATP synthase, for example M.12A diafenthiuron, or M.12B or- ganotin miticides such as azocyclotin, cyhexatin or fenbutatin oxide, or M.12C propargite, or M.12D tetradifon; M.13 Uncouplers of oxidative phosphorylation via disruption of the proton gradient, for example chlorfenapyr, DNOC or sulfluramid;\n\nM.14 Nicotinic acetylcholine receptor (nAChR) channel blockers, for example nereistoxin analogues as bensultap, cartap hydrochloride, thiocyclam or thiosultap sodium;\n\nM.15 Inhibitors of the chitin biosynthesis type 0, such as benzoylureas as for example bistriflu- ron, chlorfluazuron, diflubenzuron, flucycloxuron, flufenoxuron, hexaflumuron, lufenuron, novalu- ron, noviflumuron, teflubenzuron or triflumuron;\n\nM.16 Inhibitors of the chitin biosynthesis type 1 , as for example buprofezin;\n\nM.17 Moulting disruptors, Dipteran, as for example cyromazine;\n\nM.18 Ecdyson receptor agonists such as diacylhydrazines, for example methoxyfenozide, tebufenozide, halofenozide, fufenozide or chromafenozide;\n\nM.19 Octopamin receptor agonists, as for example amitraz;\n\nM.20 Mitochondrial complex III electron transport inhibitors, for example M.20A hydramethyl- non, or M.20B acequinocyl, or M.20C fluacrypyrim;\n\nM.21 Mitochondrial complex I electron transport inhibitors, for example M.21A METI acaricides and insecticides such as fenazaquin, fenpyroximate, pyrimidifen, pyridaben, tebufenpyrad or tolfenpyrad, or M.21 B rotenone;\n\nM.22 Voltage-dependent sodium channel blockers, for example M.22A indoxacarb, or M.22B metaflumizone, or M.22B.1 : 2-[2-(4-Cyanophenyl)-1-[3-(trifluoromethyl)phenyl]ethylidene]-N-[4- (difluoromethoxy)phenyl]-hydrazinecarboxamide or M.22B.2: N-(3-Chloro-2-methylphenyl)-2-[(4- chlorophenyl)[4-[methyl(methylsulfonyl)amino]phenyl]methylene]-hydrazinecarboxamide;\n\nM.23 Inhibitors of the of acetyl CoA carboxylase, such as Tetronic and Tetramic acid derivatives, for example spirodiclofen, spiromesifen or spirotetramat;\n\nM.24 Mitochondrial complex IV electron transport inhibitors, for example M.24A phosphine such as aluminium phosphide, calcium phosphide, phosphine or zinc phosphide, or M.24B cyanide;\n\nM.25 Mitochondrial complex II electron transport inhibitors, such as beta-ketonitrile derivatives, for example cyenopyrafen or cyflumetofen;\n\nM.28 Ryanodine receptor-modulators from the class of diamides, as for example flubendia- mide, chlorantraniliprole (rynaxypyr), cyantraniliprole (cyazypyr), tetraniliprole, or the phthalamide compounds M.28.1 : (R)-3-Chlor-N1 -{2-methyl-4-[1 ,2,2,2 -tetrafluor-1 -(trifluor- methyl)ethyl]phenyl}-N2-(1 -methyl-2-methylsulfonylethyl)phthalamid and M.28.2: (S)-3-Chlor- N 1 -{2-methyl-4-[1 ,2,2,2 -tetrafluor-1 -(trifluormethyl)ethyl]phenyl}-N2-(1 -methyl-2-methyl- sulfonylethyl)phthalamid, or the compound M.28.3: 3-bromo-N-{2-bromo-4-chloro-6-[(1-cyclo- propylethyl)carbamoyl]phenyl}-1-(3-chlorpyridin-2-yl)-1 H-pyrazole-5-carboxamide (proposed ISO name: cyclaniliprole), or the compound M.28.4: methyl-2-[3,5-dibromo-2-({[3-bromo-1 -(3- chlorpyridin-2-yl)-1 H-pyrazol-5-yl]carbonyl}amino)benzoyl]-1 ,2-dimethylhydrazinecarboxylate; or a compound selected from M.28.5a) to M.28.5d) and M.28.5h) to M.28.5I): M.28.5a) N-[4,6-di- chloro-2-[(diethyl-lambda-4-sulfanylidene)carbamoyl]-phenyl]-2-(3-chloro-2-pyridyl)-5-(trifluoro- methyl)pyrazole-3-carboxamide; M.28.5b) N-[4-chloro-2-[(diethyl-lambda-4-sulfanylidene)car- bamoyl]-6-methyl-phenyl]-2-(3-chloro-2-pyridyl)-5-(trifluoromethyl)pyrazole-3-carboxamide; M.28.5c) N-[4-chloro-2-[(di-2-propyl-lambda-4-sulfanylidene)carbamoyl]-6-methyl-phenyl]-2-(3- chloro-2-pyridyl)-5-(trifluoromethyl)pyrazole-3-carboxamide; M.28.5d) N-[4,6-dichloro-2-[(di-2- propyl-lambda-4-sulfanylidene)carbamoyl]-phenyl]-2-(3-chloro-2-pyridyl)-5-(trifluoro\n\nzole-3-carboxamide; M.28.5h) N-[4,6-dibromo-2-[(diethyl-lambda-4-sulfanylidene)carbamoyl]- phenyl]-2-(3-chloro-2-pyridyl)-5-(trifluoromethyl)pyrazole-3-carboxamide; M.28.5i) N-[2-(5- Amino-1 ,3,4 hiadiazol-2-yl)-4-chloro-6-methylphenyl]-3-bromo\n\nzole-5-carboxamide; M.28.5j) 3-Chloro-1 -(3-chloro-2-pyridinyl)-N-[2,4-dichloro-6-[[(1 -cyano-1 - methylethyl)amino]carbonyl]phenyl]-1 H-pyrazole-5-carboxamide; M.28.5k) 3-Bromo-N-[2,4-di- chloro-6-(methylcarbamoyl)phenyl]-1-(3,5-dichloro-2-pyridyl)-1 H-pyrazole-5-carboxamide;\n\nM.28.5I) N-[4-Chloro-2-[[(1 -dimethylethyl)amino]carbonyl]-6-methylphenyl]-1-(3-chloro-2-pyri- dinyl)-3-(fluoromethoxy)-1 H-pyrazole-5-carboxamide; or\n\nM.28.6: cyhalodiamide; or;\n\nM.29. insecticidal active compounds of unknown or uncertain mode of action, as for example afidopyropen, afoxolaner, azadirachtin, amidoflumet, benzoximate, bifenazate, broflanilide, bro- mopropylate, chinomethionat, cryolite, dicloromezotiaz, dicofol, flufenerim, flometoquin, fluen- sulfone, fluhexafon, fluopyram, flupyradifurone, fluralaner, metoxadiazone, piperonyl butoxide, pyflubumide, pyridalyl, pyrifluquinazon, sulfoxaflor, tioxazafen, triflumezopyrim, or the compounds\n\nM.29.3: 11-(4-chloro-2,6-dimethylphenyl)-12-hydroxy-1 ,4-dioxa-9-azadispiro[4.2.4.2]-tetradec- 11-en-10-one, or the compound\n\nM.29.4: 3-(4'-fluoro-2,4-dimethylbiphenyl-3-yl)-4-hydroxy-8-oxa-1-azaspiro[4.5]dec-3-en-2-one, or the compound\n\nM.29.5: 1-[2-fluoro-4-methyl-5-[(2,2,2-trifluoroethyl)sulfinyl]phenyl]-3-(trifluoromethyl)-1 H-1 ,2,4- triazole-5-amine, or actives on basis of bacillus firmus (Votivo, 1-1582); or\n\na compound selected from the group of M.29.6, wherein the compound is selected from M.29.6a) to M.29.6k): M.29.6a) (E/Z)-N-[1-[(6-chloro-3-pyridyl)methyl]-2-pyridylidene]-2,2,2-tri- fluoro-acetamide; M.29.6b) (E/Z)-N-[1-[(6-chloro-5-fluoro-3-pyridyl)methyl]-2-pyridylidene]-2,2,2- trifluoro-acetamide; M.29.6c) (E/Z)-2,2,2-trifluoro-N-[1-[(6-fluoro-3-pyridyl)methyl]-2-pyridyli- dene]acetamide; M.29.6d) (E/Z)-N-[1-[(6-bromo-3-pyridyl)methyl]-2-pyridylidene]-2,2,2-trifluoro- acetamide; M.29.6e) (E/Z)-N-[1 -[1-(6-chloro-3-pyridyl)ethyl]-2-pyridylidene]-2,2,2-trifluoro-acet- amide; M.29.6f) (E/Z)-N-[1 -[(6-chloro-3-pyridyl)methyl]-2-pyridylidene]-2,2-difluoro-acetamide; M.29.6g) (E/Z)-2-chloro-N-[1 -[(6-chloro-3-pyridyl)methyl]-2-pyridylidene]-2,2-difluoro-acetamide; M.29.6h) (E/Z)-N-[1-[(2-chloropyrimidin-5-yl)methyl]-2-pyridylidene]-2,2,2-trifluoro-acetamide; .29.6) (E/Z)-N-[1-[(6-chloro-3-pyridyl)methyl]-2-pyridylidene]-2,2,3,3,3-pentafluoro-propana- mide.); M.29.6j) N-[1-[(6-chloro-3-pyridyl)methyl]-2-pyridylidene]-2,2,2-trifluoro-thioacetamide; or M.29.6k) N-[1-[(6-chloro-3-pyridyl)methyl]-2-pyridylidene]-2,2,2-trifluoro-N'-isopropyl-acetam- idine; or the compounds\n\nM.29.8: fluazaindolizine; or the compounds\n\nM.29.9.a): 4-[5-(3,5-dichlorophenyl)-5-(trifluoromethyl)-4H-isoxazol-3-yl]-2-methyl-N-(1-ox- othietan-3-yl)benzamide; or M.29.9.b): fluxametamide; or\n\nM.29.10: 5-[3-[2,6-dichloro-4-(3,3-dichloroallyloxy)phenoxy]propoxy]-1 H-pyrazole; or a compound selected from the group of M.29.1 1 , wherein the compound is selected from M.29.1 1 b) to M.29.11 p): M.29.11.b) 3-(benzoylmethylamino)-N-[2-bromo-4-[1 ,2,2,3,3,3-hex- afluoro-1-(trifluoromethyl)propyl]-6-(trifluoromethyl)phenyl]-2-fluoro-benzamide; M.29.11 .c) 3- (benzoylmethylamino)-2-fluoro-N-[2-iodo-4-[1 ,2,2,2-tetrafluoro-1 -(trifluoromethyl)ethyl]-6-(trifluo- romethyl)phenyl]-benzamide; M.29.11.d) N-[3-[[[2-iodo-4-[1 ,2,2,2-tetrafluoro-1 -(trifluorome- thyl)ethyl]-6-(trifluoromethyl)phenyl]amino]carbonyl]phenyl]-N-methyl-benzam M.29.1 1.e) N- [3-[[[2-bromo-4-[1 ,2,2,2-tetrafluoro-1-(trifluoromethyl)ethyl]-6-(trifl^\n\nbonyl]-2-fluorophenyl]-4-fluoro-N-methyl-benzamide; M.29.1 1.f) 4-fluoro-N-[2-fluoro-3-[[[2-iodo- 4-[1 ,2,2,2-tetrafluoro-1 -(trifluoromethyl)ethyl]-6-(trifluoromethyl)phenyl]amin\n\nN-methyl-benzamide; M.29.1 1.g) 3-fluoro-N-[2-fluoro-3-[[[2-iodo-4-[1 ,2,2,2-tetrafluoro-1-(trifluo- romethyl)ethyl]-6-(trifluoromethyl)phenyl]amino]carbonyl]phenyl]-N-methyl-b\n\nM.29.1 1.h) 2-chloro-N-[3-[[[2-iodo-4-[1 ,2J2J2-tetrafluoro-1-(trifluoromethyl)ethyl]-6-(trifluorome- thyl)phenyl]amino]carbonyl]phenyl]- 3-pyridinecarboxamide; M.29.11.i) 4-cyano-N-[2-cyano-5- [[2,6-dibromo-4-[1 ,2,2,3,3,3-hexafluoro-1-(trifluoromethyl)propyl]phenyl]carbamoyl]pheny methyl-benzamide; M.29.1 1.j) 4-cyano-3-[(4-cyano-2-methyl-benzoyl)amino]-N-[2,6-dichloro-4- [1 ,2,2,3,3,3-hexafluoro-1 -(trifluoromethyl)propyl]phenyl]-2-fluoro-benzamide; M.29.1 1 .k) N-[5- [[2-chloro-6-cyano-4-[1 ,2,2,3,3,3-hexafluoro-1-(trifluorom\n\nano-phenyl]-4-cyano-2-methyl-benzamide; M.29.1 1 .1) N-[5-[[2-bromo-6-chloro-4-[2,2,2-trifluoro- 1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]carbamoyl]-2-cyano-phenyl]-4-cyano-2-meth zamide; M.29.1 1.m) N-[5-[[2-bromo-6-chloro-4-[1 , 2,2,3,3, 3-hexafluoro-1-(trifluoromethyl)pro- pyl]phenyl]carbamoyl]-2-cyano-phenyl]-4-cyano-2-methyl-benzamide; M.29.1 1.n) 4-cyano-N-[2- cyano-5-[[2,6-dichloro-4-[1 ,2,2,3,3,3-hexafluoro-1-(trifluoromethyl)propyl]phenyl]carbamoyl]phe- nyl]-2-methyl-benzamide; M.29.1 1.o) 4-cyano-N-[2-cyano-5-[[2,6-dichloro-4-[1 ,2,2,2-tetrafluoro- 1-(trifluoromethyl)ethyl]phenyl]carbamoyl]phenyl]-2-methyl-benzamide; M.29.1 1.p) N-[5-[[2- bromo-6-chloro-4-[1 ,2,2,2-tetrafluoro-1-(trifluorome ^\n\nnyl]-4-cyano-2-methyl-benzamide; or\n\na compound selected from the group of M.29.12, wherein the compound is selected from M.29.12a) to M.29.12m): M.29.12.a) 2-(1 ,3-Dioxan-2-yl)-6-[2-(3-pyridinyl)-5-thiazolyl]-pyridine; M.29.12.b) 2-[6-[2-(5-Fluoro-3-pyridinyl)-5-thiazolyl]-2-pyridinyl]-pyrimidine; M.29.12.c) 2-[6-[2- (3-Pyridinyl)-5-thiazolyl]-2-pyridinyl]-pyrimidine; M.29.12.d) N-Methylsulfonyl-6-[2-(3-pyridyl)thia- zol-5-yl]pyridine-2-carboxamide; M.29.12. e) N-Methylsulfonyl-6-[2-(3-pyridyl)thiazol-5-yl]pyri- dine-2-carboxamide; M.29.12.f) N-Ethyl-N-[4-methyl-2-(3-pyridyl)thiazol-5-yl]-3-methylthio-pro- panamide; M.29.12.g) N-Methyl-N-[4-methyl-2-(3-pyridyl)thiazol-5-yl]-3-methylthio-propanamide; M.29.12.h) N,2-Dimethyl-N-[4-methyl-2-(3-pyridyl)thiazol-5-yl]-3-methylthio-propanamide;\n\nM.29.12.1) N-Ethyl-2-methyl-N-[4-methyl-2-(3-pyridyl)thiazol-5-yl]-3-methylthio-propanamide; M.29.12.J) N-[4-Chloro-2-(3-pyridyl)thiazol-5-yl]-N-ethyl-2-methyl-3-methylthio-propanamide; M.29.12.k) N-[4-Chloro-2-(3-pyridyl)thiazol-5-yl]-N,2-dimethyl-3-methylthio-propanamide;\n\nM.29.12.1) N-[4-Chloro-2-(3-pyridyl)thiazol-5-yl]-N-methyl-3-methylthio-propanamide;\n\nM.29.12. m) N-[4-Chloro-2-(3-pyridyl)thiazol-5-yl]-N-ethyl-3-methylthio-propanamide; or the compounds\n\nM.29.14a) 1 -[(6-Chloro-3-pyridinyl)methyl]-1 , 2,3,5, 6,7-hexahydro-5-methoxy-7-methyl-8-nitro- imidazo[1 ,2-a]pyridine; or M.29.14b) 1-[(6-Chloropyridin-3-yl)methyl]-7-methyl-8-nitro- 1 ,2,3,5,6,7-hexahydroimidazo[1 ,2-a]pyridin-5-ol; or the compounds\n\nM.29.16a) 1 -isopropyl-N,5-dimethyl-N-pyridazin-4-yl-pyrazole-4-carboxamide; or M.29.16b) 1- (1 ,2-dimethylpropyl)-N-ethyl-5-methyl-N-pyridazin-4-yl-pyrazole-4-carboxamide; M.29.16c) N,5- dimethyl-N-pyridazin-4-yl-1 -(2,2,2-trifluoro-1 -methyl-ethyl)pyrazole-4-carboxamide; M.29.16d) 1 - [1 -(1 -cyanocyclopropyl)ethyl]-N-ethyl-5-methyl-N-pyridazin-4-yl-pyrazole-4-carboxamide; M.29.16e) N-ethyl-1-(2-fluoro-1-methyl-propyl)-5-methyl-N-pyridazin-4-yl-pyrazole-4-carbox- amide; M.29.16f) 1 -(1 ,2-dimethylpropyl)-N,5-dimethyl-N-pyridazin-4-yl-pyrazole-4-carboxamide; M.29.16g) 1-[1 -(1 -cyanocyclopropyl)ethyl]-N,5-dimethyl-N-pyridazin-4-yl-pyrazole-4-carbox- amide; M.29.16h) N-methyl-1-(2-fluoro-1 -methyl-propyl]-5-methyl-N-pyridazin-4-yl-pyrazole-4- carboxamide; M.29.16i) 1 -(4,4-difluorocyclohexyl)-N-ethyl-5-methyl-N-pyridazin-4-yl-pyrazole-4- carboxamide; or M.29.16j) 1-(4,4-difluorocyclohexyl)-N,5-dimethyl-N-pyridazin-4-yl-pyrazole-4- carboxamide, or\n\nM.29.17 a compound selected from the compounds M.29.17a) to M.29.17j): M.29.17a) N-(1 - methylethyl)-2-(3-pyridinyl)-2H-indazole-4-carboxamide; M.29.17b) N-cyclopropyl-2-(3-pyridi- nyl)-2H-indazole-4-carboxamide; M.29.17c) N-cyclohexyl-2-(3-pyridinyl)-2H-indazole-4-carbox- amide; M.29.17d) 2-(3-pyridinyl)-N-(2,2,2-trifluoroethyl)-2H-indazole-4-carboxamide; M.29.17e) 2-(3-pyridinyl)-N-[(tetrahydro-2-furanyl)methyl]-2H-indazole-5-carboxamide; M.29.17f) methyl 2- [[2-(3-pyridinyl)-2H-indazol-5-yl]carbonyl]hydrazinecarboxylate; M.29.17g) N-[(2,2-difluorocyclo- propyl)methyl]-2-(3-pyridinyl)-2H-indazole-5-carboxamide; M.29.17h) N-(2,2-difluoropropyl)-2- (3-pyridinyl)-2H-indazole-5-carboxamide; M.29.17i) 2-(3-pyridinyl )-N-(2-pyrimidinylmethyl )-2H- indazole-5-carboxamide; M.29. 7j) N-[(5-methyl-2-pyrazinyl)methyl]-2-(3-pyridinyl)-2H-indazole- 5-carboxamide, or\n\nM.29.18 a compound selected from the compounds M.29.18a) to M.29.18d): M.29.18a) N-[3- chloro-1-(3-pyridyl)pyrazol-4-yl]-N-ethyl-3-(3,3,3-trifluoropropylsulfanyl)propanamide; M.29.18b) N-[3-chloro-1-(3-pyridyl)pyrazol-4-yl]-N-ethyl-3-(3,3,3-trifluoropropylsulfinyl)propanamide;\n\nM.29.18c) N-[3-chloro-1-(3-pyridyl)pyrazol-4-yl]-3-[(2,2-difluorocyclopropyl)methylsulfanyl]-N- ethyl-propanamide; M.29.18d) N-[3-chloro-1-(3-pyridyl)pyrazol-4-yl]-3-[(2,2-difluorocyclopro- pyl)methylsulfinyl]-N-ethyl-propanamide; or the compound\n\nM.29.19 sarolaner, or the compound\n\nM.29.20 lotilaner.\n\nThe commercially available compounds of the group M listed above may be found in The Pesticide Manual, 16th Edition, C. MacBean, British Crop Protection Council (2013) among other publications. The online Pesticide Manual is updated regularly and is accessible through http://bcpcdata.com/pesticide-manual.html.\n\nAnother online data base for pesticides providing the ISO common names is http://www.alan- wood.net/pesticides.\n\nThe M.4 neonicotinoid cycloxaprid is known from WO2010/069266 and WO201 1/069456, the neonicotinoid M.4A.2, sometimes also to be named as guadipyr, is known from\n\nWO2013/003977, and the neonicotinoid M.4A.3 (approved as paichongding in China) is known from WO2007/101369. The metaflumizone analogue M.22B.1 is described in CN10171577 and the analogue M.22B.2 in CN102126994. The phthalamides M.28.1 and M.28.2 are both known from WO2007/101540. The anthranilamide M.28.3 is described in WO2005/077934. The hydra- zide compound M.28.4 is described in WO2007/043677. The anthranilamides M.28.5a) to M.28.5d) and M.28.5h) are described in WO 2007/006670, WO2013/024009 and\n\nWO2013/024010, the anthranilamide M.28.5i) is described in WO2011/085575, M.28.5j) in\n\nWO2008/134969, M.28.5k) in US201 1/046186 and M.28.5I) in WO2012/034403. The diamide compound M.28.6 can be found in WO2012/034472. The spiroketal-substituted cyclic ketoenol derivative M.29.3 is known from WO2006/089633 and the biphenyl-substituted spirocyclic ketoenol derivative M.29.4 from WO2008/067911. The triazoylphenylsulfide M.29.5 is described in WO2006/043635, and biological control agents on the basis of bacillus firmus are described in WO2009/124707. The compounds M.29.6a) to M.29.6i) listed under M.29.6 are described in WO2012/029672, and M.29.6j) and M.29.6k) in WO2013/129688. The nematicide M.29.8 is known from WO2013/055584. The isoxazoline M.29.9.a) is described in WO2013/050317. The isoxazoline M.29.9.b) is described in WO2014/126208. The pyridalyl-type analogue M.29.10 is known from WO2010/060379. The carboxamides broflanilide and M.29.1 1 .b) to M.29.1 1.h) are described in WO2010/018714, and the carboxamides M.29.1 1 i) to M.29.1 1 .p) in\n\nWO2010/127926. The pyridylthiazoles M.29.12.a) to M.29.12.c) are known from\n\nWO2010/006713, M.29.12.d) and M.29.12.e) are known from WO2012/000896, and M.29.12. ) to M.29.12.m) from WO2010/129497. The compounds M.29.14a) and M.29.14b) are known from WO2007/10 369. The pyrazoles M.29.16.a) to M.29.16h) are described in\n\nWO2010/034737, WO2012/084670, and WO2012/143317, respectively, and the pyrazoles M.29.16i) and M.29.16j) are described in US 61/891437. The pyridinylindazoles M.29.17a) to M.29.17.J) are described in WO2015/038503. The pyridylpyrazoles M.29.18a) to M.29.18d) are described in US2014/0213448. The isoxazoline M.29.19 is described in WO2014/036056. The isoxazoline M.29.20 is known from WO2014/0909 8.\n\nThe following list of fungicides, in conjunction with which the compounds of the present invention can be used, is intended to illustrate the possible combinations but does not limit them: A) Respiration inhibitors\n\n- Inhibitors of complex I II at Q0 site (e. g. strobilurins): azoxystrobin (A.1.1 ), coumethoxy- strobin (A.1 .2), coumoxystrobin (A.1.3), dimoxystrobin (A.1.4), enestroburin (A.1 .5), fenamin- strobin (A.1 .6), fenoxystrobin/flufenoxystrobin (A.1 .7), fluoxastrobin (A.1 .8), kresoxim-methyl (A.1 .9), mandestrobin (A.1 .10), metominostrobin (A.1 .1 1 ), orysastrobin (A.1 .12), picoxy.strobin (A.1 .13), pyraclostrobin (A.1.14), pyrametostrobin (A.1.15), pyraoxystrobin (A.1 .16), tri- floxystrobin (A.1 .17), 2-(2-(3-(2,6-dichlorophenyl)-1 -methyl-allylideneaminooxymethyl)-phenyl)- 2-methoxyimino-N-methyl-acetamide (A.1 .18), pyribencarb (A.1.19), triclopyricarb/chlorodincarb (A.1 .20), famoxadone (A.1 .21 ), fenamidone (A.1 .21 ), methyl- V-[2-[(1 ,4-dimethyl-5-phenyl-pyra- zol-3-yl)oxylmethyl]phenyl]-N-methoxy-carbamate (A.1.22), 1 -[3-chloro-2-[[1 -(4-chlorophenyl)- 1 H-pyrazol-3-yl]oxymethyl]phenyl]-4-methyl-tetrazol-5-one (A.1 .23), 1-[3-bromo-2-[[1-(4-chloro- phenyl)pyrazol-3-yl]oxymethyl]phenyl]-4-methyl-tetrazol-5-one (A.1 .24), 1 -[2-[[1 -(4-chloro- phenyl)pyrazol-3-yl]oxymethyl]-3-methyl-phenyl]-4-methyl-tetrazol-5-one (A.1 .25), 1-[2-[[1-(4- chlorophenyl)pyrazol-3-yl]oxymethyl]-3-fluoro-phenyl]-4-methyl-tetrazol-5-one (A.1 .26), 1 -[2-[[1 - (2,4-dichlorophenyl)pyrazol-3-yl]oxymethyl]-3-fluoro-phenyl]-4-methyl-tetrazol-5-one (A.1 .27), 1 - [2-[[4-(4-chlorophenyl)thiazol-2-yl]oxymethyl]-3-methyl-phenyl]-4-methyl-tetrazol-5-one (A.1.28), 1-[3-chloro-2-[[4-(p-tolyl)thiazol-2-yl]oxymethyl]phenyl]-4-methyl-tetrazol-5-one (A.1.29), 1-[3- cyclopropyl-2-[[2-methyl-4-(1 -methylpyrazol-3-yl)phenoxy]methyl]phenyl]-4-methyl-tetrazol-5- one (A.1 .30), 1 -[3-(difluoromethoxy)-2-[[2-methyl-4-(1 -methylpyrazol-3-yl)phenoxy]methyl]phe- nyl]-4-methyl-tetrazol-5-one (A.1 .31 ), 1-methyl-4-[3-methyl-2-[[2-methyl-4-(1 -methylpyrazol-3- yl)phenoxy]methyl]phenyl]tetrazol-5-one (A.1.32), 1 -methyl-4-[3-methyl-2-[[1 -[3-(trifluorome- thyl)phenyl]-ethylideneamino]oxymethyl]phenyl]tetrazol-5-one (A.1.33), (Z;2_r)-5-[1-(2,4-dichlo- rophenyl)pyrazol-3-yl]-oxy-2-methoxyimino-/V,3-dimethyl-pent-3-enamide (A.1 .34), (Z,2E)-b-[\\ - (4-chlorophenyl)pyrazol-3-yl]oxy-2-methoxyimino- V,3-dimethyl-pent-3-enamide (A.1 .35), {Z,2E)~ 5-[1 -(4-chloro-2-fluoro-phenyl)pyrazol-3-yl]oxy-2-methoxyimino-/V,3-dimethyl-pent-3-enamide (A.1 .36), - inhibitors of complex III at Q, site: cyazofamid (A.2.1 ), amisulbrom (A.2.2), [(3S,6S,7R,8R)- 8-benzyl-3-[(3-acetoxy-4-methoxy-pyridine-2-carbonyl)amino]-6-methyl-4,9-dioxo-1 ,5-dioxonan- 7-yl] 2-methylpropanoate (A.2.3), [(3S,6S,7R,8R)-8-benzyl-3-"
    }
}